

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G01N 33/53, 33/555, 33/567, C07K 7/00	A1	(11) International Publication Number: WO 96/14580	(43) International Publication Date: 17 May 1996 (17.05.96)
--	----	---	--

(21) International Application Number: PCT/US95/13794

(22) International Filing Date: 3 November 1995 (03.11.95)

(30) Priority Data:

335,524	7 November 1994 (07.11.94)	US
469,141	6 June 1995 (06.06.95)	US

(60) Parent Applications or Grants

(63) Related by Continuation

US	335,524 (CIP)
Filed on	7 November 1994 (07.11.94)
US	469,141 (CIP)
Filed on	6 June 1995 (06.06.95)

(71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MUMFORD, Richard, A. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). DAVIES, D., T., Philip [GB/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). DAHLGREN, Mary, E. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).

(US). BOGER, Joshua, S. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). HUMES, John, L. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).

(74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).

(81) Designated States: CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published

*With international search report.**Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: ASSAY FOR MARKER OF HUMAN POLYMORPHONUCLEAR LEUKOCYTE ELASTASE ACTIVITY

(57) Abstract

A radioimmunoassay (RIA) based on the A α (Val³⁶⁰) epitope which allows the evaluation of the potency of compounds that inhibit formation of cleavage products containing this neoepitope in a variety of *in vitro* cell biological situations is provided. The new RIA may be to detect an endogenous A α (Val³⁶⁰) signal in normal human plasma and at elevated levels in cystic fibrosis plasma and in rheumatoid arthritis synovial fluid samples. The assay procedure is a single step assay which allows for the rapid and reproducible detection of specific cleavage peptides.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

TITLE OF THE INVENTION**ASSAY FOR MARKER OF HUMAN POLYMORPHONUCLEAR
LEUKOCYTE ELASTASE ACTIVITY****5 CROSS-RELATED TO OTHER APPLICATIONS**

This is a continuation-in-part of U. S. Serial Number 08/469,141, filed June 6, 1995, now pending, which is a continuation-in-part of U.S. Serial Number 08/335,524 filed November 7, 1994, now pending, which is a continuation-in-part of U.S. Serial Number 10 08/196,663, filed February 15, 1994, now pending, which is expressly incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows neoepitopes generated by cleavage of the 15 A α -chain of human fibrinogen by PMV elastase.

Figure 2 shows a standard displacement curve for A α (Val³⁶⁰) assay. The standard peptide (YRGSAGHWTSESSV) was incubated overnight with R-770 antiserum and ¹²⁵I-YRGSAGHATSESSV probe-peptide. The antibody bound radioactivity 20 was separated from the unbound radioactivity and the percent bound in the presence of standard peptide was calculated relative to the amount bound in the absence of competitive peptide. Only unknown sample values falling between 20-80% were used for calculations.

Figure 3 shows variation of quality control standards in the 25 A α (Val³⁶⁰) RIA.

Standard peptide solutions (20, 6 and 2nM) were incubated in each assay to determine the variation of the RIA. The amount recovered was determined from the standard curve each day. Assays in which the standards fell outside the 2 SD limit were omitted.

Figure 4 shows specificity of R-770 A α (Val³⁶⁰) antiserum 30 (C-terminal deletions).

A series of peptides with sequential deletions of C-terminal amino acids were incubated with R-770 antiserum and ¹²⁵I-YRGSAGHATSESSV probe-peptide. When the C-terminal valine was

- 2 -

truncated to form AGHWTSESS³⁵⁹ there was no recognition by the antiserum. These data confirm the requirement for the free carboxy terminal Val for recognition by the antibody.

5 Figure 5 shows specificity of R-770 A α (Val³⁶⁰) antiserum (C-terminal extensions).

A series of peptides spanning the PMNE cleavage site were incubated with R-770 antiserum and with ¹²⁵I-YRGSAGHATSESSV probe-peptide. The addition of a single amino acid, Ser, to form AGHWTSESSVS³⁶¹ resulted in a 300-fold loss in antibody recognition.
10 Other spanning peptides were not recognized. These data confirmed the requirement for the free carboxy terminal Val for recognition by the antibody.

Figure 6 shows specificity of R-770 A α (Val³⁶⁰) antiserum (N-terminal deletions).

15 A series of peptides to characterize the minimum length of peptide necessary for maximal recognition were incubated with R-770 antiserum and ¹²⁵I-YRGSAGHATSESSV probe peptide. WTSESSV was determined to be the minimum sequence required for optimal recognition by R-770 antiserum.

20 Figure 7 shows specificity of R-770 A α (Val³⁶⁰)(C-terminal substitutions).

A series of peptides with various substitutions for the carboxy terminal Val were incubated with R-770 antiserum and ¹²⁵I-YGRSAGHATSESSV probe peptide. The amidation of Val-COOH to Val-CONH₂ as well as the substitution of D-Val for L-Val resulted in a
25 marked loss of recognition. Replacement of Val with Thr or Ile resulted in a 10-100 fold loss of recognition respectively. The replacement with Leu resulted in a complete loss of recognition.

30 Figure 8 shows the competitive displacement of ¹²⁵I-A α (Val³⁶⁰) with standard peptide, commercial fibrinogen and immunoadsorbed fibrinogen.

A commercial preparation of human fibrinogen was incubated with R-770 antiserum and ¹²⁵I-YRGSAGHATSESSV probe-peptide as described in Materials and Methods. The apparent slight

- 3 -

cross-reactivity was removed by immunoadsorption with R-770. These data suggest that A α (Val³⁶⁰) is endogenously present in commercial preparations of fibrinogen and that R-770 does not recognize the intact (non-cleaved) molecule.

5 Figure 9 shows commercial preparations of human fibrinogen contain the A α (Val³⁶⁰) neoepitope.

A α (Val³⁶⁰) neoepitope is present in human fibrinogen. A commercial preparation of fibrinogen was evaluated by Western immunoblot analysis developed with alkaline phosphatase. A 42 kDa
10 immunoreactive protein was detected with R-770 antiserum at about 42 kDa. No signal was found with the preimmune antiserum. The immunoreactive component was blocked by the standard peptide (10 μ M) that spanned across the PMNE cleavage site.

15 Figure 10 shows PMN elastase incubated with human fibrinogen forms A α (Val³⁶⁰) neoepitope in a time-dependent manner.

Human fibrinogen was incubated with PMNE as a function of time at an enzyme to substrate ratio of 1:250. The amount of A α (Val³⁶⁰) was determined by RIA.

20 Figure 11 shows PMN elastase and proteinase 3 hydrolyze human fibrinogen to form A α (Val³⁶⁰).

Fibrinogen was incubated with PMNE and PR3 at 37°C as a function of time at an enzyme to fibrinogen ratio of 1:500 as described in Materials and Methods. The amount of A α (Val³⁶⁰) was determined by RIA. PR3 hydrolyzed fibrinogen at 15% of the rate of PMNE.

25 Figure 12 shows the effect of various proteinases to Hydrolyze human fibrinogen to produce A α (Val³⁶⁰).

Generation of A α (Val³⁶⁰) from fibrinogen in PMNE and PR3. Fibrinogen was incubated with PMNE and other proteinases at 37°C at an enzyme to substrate ratio of 1:500. Aliquots were analyzed
30 by Western blot. An intense immunoreactive component at 42 kDa was formed by PMNE and to a lesser amount by PR3. The human serine proteinases (plasmin and trypsin) showed no additional immunostaining over the endogenous A α (Val³⁶⁰) in the fibrinogen substrate. Likewise, the cysteine proteinases (Cat B, H and L) did not generate A α (Val³⁶⁰).

- 4 -

However, porcine pancreatic elastase showed a detectable A α (Val³⁶⁰) signal.

Figure 13 shows that EDTA prevents the degradation of the A α (Val³⁶⁰) ¹²⁵I-peptide probe in human plasma.

5 ¹²⁵I-YRGSAGHATSESSV probe peptide (200,000 cpm) was incubated for 60 minutes at 37°C with 100 μ l of plasma containing 31 mM EDTA. The incubation mixtures were extracted into acetone, centrifuged and the supernatant chromatographed on RP-HPLC. Fractions (500 μ l) were collected and the radioactivity of each
10 determined. This data demonstrates that EDTA (31 mM) prevented degradation of the ¹²⁵I probe peptide. ¹²⁵I probe peptide destruction by plasma would result in a false positive signal

Figure 14 shows limited digest of fibrinogen by human PMN elastase.

15 Characterization of a limited fibrinogen (FGN) digest by PMNE. A limited fibrinogen digest was prepared by incubation of PMNE with fibrinogen at an enzyme to substrate ration of 1:500 for 30 minutes. Aliquots were analyzed by Western immunoblot. Fibrinogen alone contained an endogenous 42 kDa immunoreactive species.
20 Incubation of fibrinogen with PMNE formed an intense immunoreactive band at 42 kDa (the predicted MW).

Figure 15 shows identification of A α (Val³⁶⁰) neoepitope in normal human plasma by western blot analysis.

25 Normal plasma contains endogenous A α (Val³⁶⁰) neoepitope. Two plasma samples from normal individuals were analyzed by Western immunoblot using ECL detection. A 42 kDa species was seen in both samples. This immunoreactive band was blocked by standard peptide (10 μ M) but not by a peptide spanning (10 μ M) the PMNE cleavage site.

30 Figure 16 shows the formation of A α (Val³⁶⁰) in human blood incubated with A23187.

Time dependent formation of A α (Val³⁶⁰) in human blood incubated with the calcium ionophore A23187. Aliquots of human blood (1 ml) were incubated for various times with DMSO or A23187 (150

- 5 -

µm). Plasma was prepared and the concentration Aα (Val³⁶⁰) was determined by RIA. The insert showed Western immunoblot analysis of the time course.

Figure 17 shows the calcium ionophore A23187
5 concentration dependent formation of Aα (Val³⁶⁰) in human blood.

Human blood was incubated with increasing concentrations of the calcium ionophore A23187. Maximal formation of Aα (Val³⁶⁰) neopeptide was achieved at 75 µM A23187.

Figure 18 shows that L-694,458 inhibits generation of the
10 fibrinogen cleavage product Aα (Val³⁶⁰) in A23187-stimulated human blood in a concentration-dependent manner.

L-694,458 inhibited for formation of Aα (Val³⁶⁰) in human blood. Human blood was incubated with various concentration of L-694,458. After 10 minutes, A23187 was added. Plasma was prepared
15 after an additional 1 hour of incubation. L-694,458 inhibited the A23187-induced Aα (Val³⁶⁰) formation in a dose dependent manner with an IC₅₀=0.3 µM. The insert showed Western immunoblots consistent with the RIA results.

Figure 19 shows the correlation between concentrations of
20 Aα (Val³⁶⁰) and elastase: α₁PI complex in plasma from cystic fibrosis patients and normal donors.

Aα (Val³⁶⁰) and PMNE:α₁PI complex concentrations in plasma from cystic fibrosis patients and normal donors. In a preliminary experiment to complete assay validation, arterial plasma samples from 25
25 cystic fibrosis patients and 5 normal volunteers were analyzed by RIA for Aα (Val³⁶⁰) and by ELISA for PMNE:α₁PI complexes. The insert shows selected CF and normal samples analyzed by Western immunoblot. An excellent correlation is observed between Aα (Val³⁶⁰) and PMNE: α₁PI concentrations (R=0.99).

Figure 20 shows the identification of Aα (Val³⁶⁰)
30 neopeptide in rheumatoid arthritis and gout synovial fluid.

Western immunoblot of Aα (Val³⁶⁰) neopeptide in synovial fluids. Synovial fluids from patients with various joint diseases were analyzed by Western blot. In contrast to plasma which showed

- 6 -

predominately a single 42 kDa immunostaining band, synovial fluid contained an additional component at 20 kDa, suggesting an additional cleavage of fibrinogen.

Figure 21 is a table which shows the recovery of standard peptide and limited elastase fibrinogen digest containing A α (Val³⁶⁰) from human blood.

Fibrinogen digest (FD) (9.74 pmoles) and the A α (Val³⁶⁰) standard peptide (SP) (20 pmoles) were added to 1 ml aliquots of human blood in the presence or absence of EDTA (22.7 mM). The samples were incubated at 37°C for 1 hour; centrifuged and the plasma collected. EDTA (31 mM) was added to the plasma derived from blood not incubated with EDTA. The concentration of A α (Val³⁶⁰) in the plasma was determined by RIA. Note: The hematocrit of the donor was 38.9%, thus the plasma concentration of the FD=16.0 nM and the plasma concentration of SP=32.8 nM. These data indicate that the A α (Val³⁶⁰) neoepitope can be quantitatively recovered from blood containing 31 mM EDTA.

Figure 22 is a table which shows normal human plasma contains the fibrinopeptide A α (Val³⁶⁰).

Blood was collected into heparin by antecubital venipuncture or from the radial artery. Plasma was prepared and the concentration of A α (Val³⁶⁰) determined by RIA. These data are the first direct demonstration of PMNE activity in apparently healthy individuals.

Figure 23 is a table which shows the concentration of A α (Val³⁶⁰) formed in human blood incubated with DMSO and A23187.

Aliquots of human blood (1 ml) were incubated at 37°C with A23187 (150 μ M) or DMSO. After 60 minutes the samples were centrifuged. Plasma aliquots (350 μ l) were added to 50 μ l 250 mM EDTA. The amounts of A α (Val³⁶⁰) were determined by RIA. The data have been corrected for recovery of "Limited Elastase Fibrinogen Digest" (either 0.97 pmoles or 23.7 pmoles were added to 1 ml of blood) and for EDTA dilution. This is expressed as pmoles/ml of plasma as well as being corrected for the number of PMN (1×10^6). These data show that

- 7 -

A α (Val³⁶⁰) was found in human blood incubated with A23187. An approximate 7-fold increase was observed over the endogenous signal.

Figure 24 is a table which shows the concentration of A α (Val³⁶⁰) neoepitope in synovial fluids.

5 EDTA (to yield a final concentration of 31 mM) was added to aliquots of synovial fluids and the concentration of A α (Val³⁶⁰) determined by RIA. A PMNE generated fibrinogen digest containing A α (Val³⁶⁰) was also added as a recovery standard. The data have been corrected for the recovery of the fibrinogen digest. These data
10 demonstrate the activity of PMNE in rheumatoid arthritis and gout synovial fluid samples.

BACKGROUND OF THE INVENTION

Human polymorphonuclear leukocyte elastase (PMNE)
15 cleaves human fibrinogen at multiple sites. Cleavage of the A α chain at A α (Val³⁶⁰-Ser³⁶¹) generates a stable product as indicated by its presence in biological fluids. A radioimmunoassay (RIA) based on the A α (Val³⁶⁰) epitope of this cleavage site has been developed which allows the evaluation of the potency of elastase inhibitors to inhibit
20 formation of cleavage products containing this neoepitope in a variety of *in vitro* cell biological situations. The RIA detects an endogenous A α (Val³⁶⁰) in normal human plasma and at elevated concentrations in cystic fibrosis plasma and in rheumatoid arthritis synovial fluid samples.

Human leukocyte proteinases, elastase in particular, have
25 been implicated in the pathogenesis of various connective tissue destructive diseases including pulmonary emphysema, chronic bronchitis, cystic fibrosis, bronchiectasis, acute respiratory distress syndrome, arthritis, glomerulonephritis, psoriasis, vasculitis and atherosclerosis. Elastase may also be involved in other lung diseases such as PiZZ
30 emphysema and infantile respiratory distress syndrome and in myelogenous leukemia and gout. Elastase, a serine proteinase active at neutral pH, is stored in the azurophilic granules of polymorphonuclear leukocytes and in lysosomes of transient mononuclear leukocytes. Elastase as used herein is defined as elastase derived from leukocytes.

- 8 -

Leukocyte as used herein includes neutrophils, macrophages and monocytes. Cellular elastase is released in tissues when the cell encounters matter (such as a pathogen) to be phagocytized or undergoes cellular autolysis. Tissue pathology occurs when the released elastase encounters endogenous connective tissue substrates such as elastin, proteoglycan, types III and IV collagen and fibrinonectin. In addition to connective tissue components, human leukocyte elastase hydrolyzes various plasma proteins including immunoglobulins, fibrin, fibrinogen and complement proteins.

Extracellular PMNE activity is controlled by circulating or locally produced elastase inhibitors. Circulating elastase inhibitors include alpha-1-proteinase inhibitor and alpha-2-macroglobulin. Alpha-1-proteinase inhibitor is the most prevalent regulator of endogenous elastase activity and blocks enzyme activity by complexing with the elastase so that it is unable to act on other substrates. The enzyme-inhibitor complexes are then cleared from the tissues and circulation.

Elastase and the other leukocyte associated proteinases have also been implicated in the alternate fibrinolytic pathway responsible for the dissolution of fibrinogen and fibrin. The fibrinolytic activity may be physiologically important in the thrombi reduction but may also lead to pathological conditions related to blood coagulation.

A thorough understanding of the role of leukocyte elastase in both physiological and pathological states has been hampered by the absence of a quick, efficient and reliable assay for detecting enzymatic activity *in vivo* with a natural substrate such as human fibrinogen. Direct measurement of the enzymatic activity of released PMNE is difficult because the released enzyme rapidly binds to the substrate or to serum proteinase inhibitors. Bound enzyme may be quickly removed from the circulation. Immunoassay determinations of released enzyme do not distinguish between free enzyme and enzyme bound to inhibitor, and determinations of enzyme-inhibitor complexes have the disadvantage that they detect only the inactivated enzyme.

Since direct detection of enzymatically active PMNE in physiological fluids has not proven reliable, alternate assay procedures

- 9 -

dependent upon the detection of PMNE cleavage products have been designed. Two of these methods have used elastase-cleaved products of elastin as markers. One method measured urinary desmosine, a major cross-linking amino acid of elastin, by radioimmunoassay. No consistent
5 difference has been observed between healthy individuals and chronic lung disease patients. A similar result has been reported using ELISA measurements of elastase-generated elastin-derived peptides in serum of lung disease patients and normal controls.

Assays designed to detect plasmin-generated fibrinogen
10 degradation products (FDP) have been used to detect fibrinogen cleavage products. Early assays utilized antibodies reactive with human FDP prepared by human plasmin digestion of human fibrinogen at room temperature for 12 to 36 hours, U.S. Patent 3,912,805. The antibodies are attached to red blood cells and are used in passive agglutination assays to
15 detect FDP. Antibodies to purified FDP fragments such as fragments D and E have also been employed to identify and quantify fibrinogen degradation products, U.S. Patent 4,090,846. The assay consisted of an indirect method in which human serum or urine were mixed with the antiserum to the purified D and E fragments, to which was added FDP
20 bound to latex beads. Other fibrinogen fragments have been used to produce antibody that can be used to detect the fragments in blood. Plasminogen derived fragments such as Fg-E have been described by Chen and Schulof, *Thrombos. Res.* 16: 601-615 (1979) and antibodies to the fragment have been used in radioimmunoassay to detect the fragment
25 in plasma.

Fibrinogen degradation products prepared by digesting human fibrinogen with PMNE have been used to develop assays for evaluating elastase cleavage products in fluids. Human fibrinogen was digested with PMNE at 1:50 (w/w) enzyme-to-substrate ratio for 24 hrs.
30 at 37°C. The predominant fragment was a D-like fragment of 80,000 MW and designated D_e. Antibody to this fragment retained its capacity to recognize the D_e in radioimmunoassays after adsorption with intact fibrinogen and plasmin degradation products. Plow et al. suggested that this indicated the recognition of an elastase-elicited neoantigen that was

- 10 -

only expressed by elastase degradation products. When elastase degradation products were added to normal plasma, the elastase-elicited neoantigen could be quantitatively detected in radioimmunoassay. The principal disadvantage of the fibrinogen degradation product assay procedures is that the material being assayed is defined only operationally. The sites of PMNE (or plasmin) cleavage have not been adequately defined. Consequently, the specificity of the antisera cannot be rigorously investigated and the exact nature of the products measured in the immunoassay is unknown.

Immunoassays designed to detect products of thrombin cleavage of fibrinogen have been described in several animal species. For example, a radioimmunoassay has been described which identifies the peptide F-CB1 α from the amino end of bovine fibrinogen A α chain. Thrombin cleavage of F-CB1 yielded two fragments: fibrinopeptide A (residues A α 1-16; residues 1-19; equivalent to human residues 1-16) and the carboxy-terminal fragment Th2 (residues 20-54; equal to human residues 17-51).

Fibrinopeptide A (FPA), the 1-16 amino acid residue of the A α chain (A α 1-16), is released by thrombin cleavage and have been used to produce antibodies which can be employed to assay for the fibrinogen cleavage product FPA. Antibodies reactive with FPA were used to study the human elastase cleavage products of human fibrinogen. It was found that the elastase degradation products were different from the thrombin degradation products as determined by radioimmunoassays specific for FPA. The elastase cleavage product was slightly larger than FPA and could be distinguished from FPA by immunological means.

Antibody specifically reactive with FPA has been used to evaluate *in vivo* human leukocyte elastase activity. Weitz et al. found that leukocyte elastase cleaves fibrinogen into a fibrinopeptide A-containing fragment which can be used as an index of elastase activity. Human leukocyte elastase cleaves a 21 amino acid peptide, fibrinogen A α 1-21 from the amino terminus of the alpha chain of human fibrinogen. This A α 1-21 peptide contains the entire FPA peptide. The Weitz assay does not directly measure the elastase cleavage product, but

- 11 -

measures FPA, A α 1-16, which is the normal human thrombin cleavage product of human fibrinogen. The Weitz two step radioimmunoassay utilized fresh human plasma, ethanol treated, presumably totally fibrinogen depleted, either treated or untreated with human thrombin.

5 The difference in immunoreactive FPA, A α 1-16, between the thrombin treated and untreated samples is attributed to the amount of A α 1-21 present in the original sample. This assay does not directly measure an elastase cleavage product in body fluids and requires a two-step process to detect what appears to be a single elastase cleavage product.

10 The development of assays to determine the biochemical efficacy and potency of elastase inhibitors has evolved around the need to measure the activity of PMNE under a variety of circumstances in man. The evaluation of the extracellular activity of PMNE in both
15 physiological and pathological states has been hampered by the lack of a specific assay to detect its activity *in vivo*. The direct measurement of the enzymatic activity of extracellular PMNE is difficult because the released enzyme binds to substrates and to plasma proteinase inhibitors almost immediately upon its release from PMN. Detection of enzyme by
20 immunoassays does not distinguish between free enzyme and enzyme bound to inhibitors; the disadvantage of immunoassays that measure levels of enzyme inhibitors is that they detect only the inactivated enzyme.

Human fibrinogen is a hetero-dimeric glycoprotein consisting of 3 non-identical chains, A α , B β and γ . PMNE cleaves human
25 fibrinogen at multiple sites. Primary sites of cleavage include A α (Val²¹-Glu²²), A α (Val³⁶⁰-Ser³⁶¹), A α (Val⁴⁵⁰-Ile⁴⁵¹), A α (Val⁴⁶⁴-Thr⁴⁶⁵), A α (Met⁴⁷⁶-Asp⁴⁷⁷), A α (Thr⁵⁶⁸-Ser⁵⁶⁹), γ (Thr³⁰⁵-Ser³⁰⁶), γ (Val³⁴⁷-Tyr³⁴⁸) and γ (Ala³⁵⁷-Ser³⁵⁸). We have developed two antipeptide antibodies, one of which specifically measures
30 PMNE hydrolysis of fibrinogen at the A α (Val²¹-Glu²²) position to release a 21 residue N-terminal peptide, and a second which measures cleavage at A α (Val³⁶⁰-Ser³⁶¹), to release a 250 residue C-terminal fragment (Figure 1). The A α (Val³⁶⁰) carboxyl terminal fragment remains associated with the β and γ chains of fibrinogen due to the

- 12 -

disulfide network of the protein. Neither of the 2 specific antisera recognize intact fibrinogen. Both of these RIA allow the evaluation of the potency of PMNE inhibitors, such as elastase inhibitors, to inhibit fibrinopeptide neoepitope generation in whole blood stimulated with the calcium ionophore A23187. However, a major disadvantage of the $\text{A}\alpha(\text{Val}^{21})$ assay is the rapid *in vivo* clearance and metabolism of the peptide neoepitope $\text{A}\alpha(\text{Val}^{21})$ ($t_{1/2}$ of 30 sec in both the dog and rhesus monkey). In an extensive series of experiments we were unable to detect the $\text{A}\alpha(\text{Val}^{21})$ neoepitope in normal human plasma or in plasma samples from PiZZ individuals, nor in plasma from patients with cystic fibrosis, emphysema or chronic bronchitis.

The $\text{A}\alpha(\text{Val}^{360})$ neoepitope is associated with a large protein fragment which results in a substantially slower clearance rate than $\text{A}\alpha(\text{Val}^{21})$ peptide. Utilizing the $\text{A}\alpha(\text{Val}^{360})$ RIA an endogenous signal is detected in normal human plasma. This signal is elevated in cystic fibrosis plasma samples. In addition, levels of $\text{A}\alpha(\text{Val}^{360})$ neoepitope are elevated in both rheumatoid arthritis and gout synovial fluid but not in osteoarthritis synovial fluid.

This assay may be readily incorporated into a diagnostic kit for measuring PMNE activity in man. The assay measures the potency of elastase inhibitors in plasma, sputum and synovial fluid following oral administration of drug. In a Phase I clinical study with elastase inhibitors, the $\text{A}\alpha(\text{Val}^{360})$ RIA in combination with assays of AAPVase activity and L-740,447 formation in blood, would provide data indicating the extent of inhibition of enzyme activity within cells (AAPVase in isolated PMN), generation of PMNE:elastase inhibitor complexes (L-740,447 assay) in whole blood and upon its release from cells to act on extracellular substrate [$\text{A}\alpha(\text{Val}^{360})$ neoepitope]. In subsequent clinical studies in cystic fibrosis patients, lowering of elevated levels of $\text{A}\alpha(\text{Val}^{360})$ would provide direct evidence of inhibition of PMNE activity.

The present invention is a radioimmunoassay (RIA) based on the $\text{A}\alpha(\text{Val}^{360})$ epitope which allows the evaluation of the potency of elastase inhibitors to inhibit formation of cleavage products containing

- 13 -

this neoepitope in a variety of *in vitro* cell biological situations. This new RIA detects an endogenous A α (Val³⁶⁰) signal in normal human plasma and at elevated levels in cystic fibrosis plasma and in rheumatoid arthritis synovial fluid samples. The assay procedure is a single step assay which allows for the rapid and reproducible detection of a PMNE-specific cleavage peptide.

SUMMARY OF THE INVENTION

The present invention is a radioimmunoassay based on the A α (Val³⁶⁰) epitope which allows the evaluation of the potency of elastase inhibitors to inhibit formation of cleavage products containing this neoepitope in a variety of *in vitro* cell biological situations. This new RIA detects an endogenous A α (Val³⁶⁰) normal human plasma and elevated levels of A α (Val³⁶⁰) in cystic fibrosis plasma and in rheumatoid arthritis synovial fluid samples. This RIA can monitor the severity of disease and evaluate the efficacy of PMNE inhibitors *in vivo*. The assay procedure is a single step assay which allows for the rapid and reproducible detection of PMNE-specific cleavage peptide.

DETAILED DESCRIPTION OF THE INVENTION

The invention is a radioimmunoassay based on the A α (Val³⁶⁰) epitope which allows the evaluation of the potency of elastase inhibitors to inhibit formation of cleavage products containing this neoepitope in a variety of *in vitro* cell biological situations. This RIA detects an endogenous A α (Val³⁶⁰) normal human plasma and elevated levels of A α (Val³⁶⁰) in cystic fibrosis plasma and in rheumatoid arthritis synovial fluid samples. Thus, this RIA can monitor the severity of disease and evaluate the efficacy of PMNE inhibitors *in vivo*. The assay procedure is a single step assay which allows for the rapid and reproducible detection of PMNE-specific cleavage peptide.

Human polymorphonuclear leukocyte elastase (PMNE) cleaves human fibrinogen at multiple sites. Cleavage of the A α chain at A α (Val³⁶⁰-Ser³⁶¹) generates a stable product as indicated by its presence in from biological fluids.

- 14 -

Human fibrinogen is a hetero-dimeric glycoprotein consisting of 3 non-identical chains, A α , B β and γ . PMNE cleaves human fibrinogen at multiple sites. Primary sites of cleavage include A α (Val²¹-Glu²²), A α (Val³⁶⁰-Ser³⁶¹), A α (Val⁴⁵⁰-Ile⁴⁵¹), A α (Val⁴⁶⁴-Thr⁴⁶⁵), A α (Met⁴⁷⁶-Asp⁴⁷⁷), A α (Thr⁵⁶⁸-Ser⁵⁶⁹), γ (Thr³⁰⁵-Ser³⁰⁶), γ (Val³⁴⁷-Tyr³⁴⁸) and γ (Ala³⁵⁷-Ser³⁵⁸). We have developed two antipeptide antibodies, one of which specifically measures PMNE hydrolysis of fibrinogen at the A α (Val²¹-Glu²²) position to release a 21 residue N-terminal peptide, and a second which measures cleavage at A α (Val³⁶⁰-Ser³⁶¹), to release a 250 residue C-terminal fragment (Figure 1). The A α (Val³⁶⁰) carboxyl terminal fragment remains associated with the β and γ chains of fibrinogen due to the disulfide network of the protein. Neither of the 2 specific antisera recognize intact fibrinogen. Both of these RIAs allow the evaluation of the potency of PMNE inhibitors, such as elastase inhibitors, to inhibit fibrinopeptide neoepitope generation in whole blood stimulated with the calcium ionophore A23187. However, a major disadvantage of the A α (Val²¹) assay is the rapid *in vivo* clearance and metabolism of the peptide neoepitope A α (Val²¹) (t_{1/2} of 30 sec in both the dog and rhesus monkey). In an extensive series of experiments we have been unable to detect the A α (Val²¹) neoepitope in normal human plasma or in plasma samples from PiZZ individuals, nor in plasma from patients with cystic fibrosis, emphysema or chronic bronchitis.

The A α (Val³⁶⁰) neoepitope is associated with a large protein fragment which results in a substantially slower clearance rate than A α (Val²¹) peptide. Utilizing the A α (Val³⁶⁰) RIA an endogenous signal is detected in normal human plasma. This signal is elevated in cystic fibrosis plasma samples. In addition, levels of A α (Val³⁶⁰) neoepitope are elevated in both rheumatoid arthritis and gout synovial fluid but not in osteoarthritis synovial fluid.

This assay may be incorporated into a diagnostic kit for measuring PMNE activity in man. This assay will allow the evaluation of the potency of elastase inhibitors in plasma, sputum and synovial fluid following oral administration of drug.

- 15 -

The present invention relates to the identification of time dependent, major human leukocyte elastase cleavage sites within an intact fibrinogen molecule. The structure of mammalian fibrinogen is known in the art and the human fibrinogen amino acid sequence has been schematically depicted by Doolittle, *Ann. N.Y. Acad. Sci.* 408: 13-26 (1983). The amino acid sequences in human fibrinogen have been characterized by Henschen *et al.*, *Ann. N.Y. Acad. Sci.* 408: 28-43 (1983). The enzymatic cleavage sites are determined by reacting human fibrinogen (Sigma), about 200 nanomoles, with HLE (Elastin Products) or monocyte elastase, about 1 nanomole, at about 37°C for various times periods ranging from about 0 minutes to about 2 hours. The reactions are carried out in an acceptable buffer, preferably Tris, at a pH of about 7.0 in a final volume of about 1.0 ml. Each reaction is stopped by the addition of cold alcohol, preferably ethanol at about 3°C and incubated at about 3°C for about 30 minutes. Following incubation the suspension is centrifuged at about 3,000 x g at about 3°C for about 20 minutes. The supernatant fluid is collected and transferred to clean tubes and concentrated to dryness in a Speed-Vac for about 16 hours. Each sample is reconstituted in an acceptable high performance liquid chromatography (HPLC) buffer, preferably water and acetonitrile mixtures and chromatographed on a C1-18 Dupont-Zorbax™ column, about 0.4 X 25 cm. The peptides are eluted with a linear gradient consisting of about H₂O:acetonitrile:trifluoroacetic acid 95:5:0.2 v/v/v, to about H₂O:acetonitrile:trifluoroacetic acid 60:40:0.2 v/v/v. Peptide peaks are collected, re-chromatographed to demonstrate purity and subjected to N-terminal amino acid sequence analysis on an Applied Biosystems Protein Peptide Sequencer, Model 470A. Eight major peaks are identified and the amino acid sequences are used to determine the sites of HLE cleavage. Nineteen minor amino acid peaks are also identified and can be used to identify minor or secondary HLE cleavage sites. The major HLE cleavage sites are shown in the following table.

- 16 -

TABLE IMajor Human Leukocyte Elastase Cleavage Sites in Human Fibrinogen

Chain	Site
1. A alpha	21-----22 Val Glu
2. A alpha	360-----361 Val Ser
3. A alpha	450-----451 Val Ile
4. A alpha	464-----465 Val Thr
5. A alpha	476-----477 Met Asp
6. A alpha	568-----569 Thr Ser
7. gamma	305-----306 Thr Ser
8. gamma	347-----348 Val Tyr
9. gamma	357-----358 Ala Ser

- 17 -

Knowing the specific elastase cleavage sites of human fibrinogen allows the synthesis of antigenic peptides and peptide probes of varying amino acid length corresponding to both the amino and carboxyl termini of the primary cleavage sites. Antigenic peptide as used
5 herein denotes a peptide that can combine with or bind to specific antibody raised against the antigen or can induce the formation of antibody which will react with the antigen. The preferred embodiment of antigenic peptides and peptide probes includes, but is not limited to the first 15 amino acids on either the carboxyl or amino side of described
10 enzymatic cleavage sites. It is to be understood that the embodiment of this invention includes peptides ranging in length from about 5 amino acids to about 25 amino acids or longer. All amino acid sequences depicted herein are numbered from the amino terminus to carboxyl terminus according to the scheme shown by Henschen *et al.*, Ann. N.Y.
15 Acad. Sci. 408: 28-43 (1983).

Representative carboxyl termini antigenic peptide and probe peptide amino acid sequences are shown in the following table.

- 18 -

TABLE 2Carboxyl Terminus Antigenic Peptides

5	A alpha chain	
	7	21
	1. Asp Phe Leu Ala Glu Gly Gly Gly Val Arg Gly Pro Arg Val Val	
	346	360
10	2. Ser Glu Arg Gly Ser Ala Gly His Trp Thr Ser Glu Ser Ser Val	
	436	450
	3. Thr Thr Thr Arg Arg Ser Cys Ser Lys Thr Val Thr Lys Thr Val	
15	450	464
	4. Val Ile Gly Pro Asp Gly His Lys Glu Val Thr Lys Glu Val Val	
	462	476
20	5. Glu Val Val Thr Ser Glu Asp Gly Ser Asp Cys Pro Glu Ala Met	
	554	568
	6. Arg Gly Lys Ser Ser Ser Tyr Ser Lys Gln Phe Thr Ser Ser Thr gamma chain	
25	291	305
	1. Asp Gly Phe Asp Phe Gly Asp Asp Pro Ser Asp Lys Phe Phe Thr	
	333	347
30	2. Gly Trp (Trp)* Met Asn Lys Cys His Ala Gly His Leu Asn Gly Val	
	343	357
	3. His Leu Asn Gly Val Tyr Tyr Gln Gly Gly Thr Tyr Ser Lys Ala	

*Tentative amino acid assignment.

- 19 -

The specificity of the antigenic peptides and the peptide probes is determined by the epitope directly adjacent to the amino or carboxyl terminus of the enzyme cleavage site. Epitope as used herein denotes an antigenic determinant site of known structure, amino acid sequence, which is responsible for the specificity of the antigen and can react specifically with antibody raised against the antigen which contains the epitope. The preferred embodiment of epitopes includes, but is not limited to, the first 5 amino acids on either the carboxyl or amino side of the described enzymatic cleavage sites. Representative carboxyl terminus epitope amino acid sequences are shown in the following table.

TABLE 3**Carboxyl Terminus Epitopes Peptides**

15

A alpha chain

- | | |
|------------------------|-----|
| 17 | 21 |
| 1. Gly Pro Arg Val Val | |
| 356 | 360 |
| 2. Ser Glu Ser Ser Val | |
| 446 | 450 |
| 3. Val Thr Lys Thr Val | |
| 460 | 464 |
| 4. Thr Lys Glu Val Val | |
| 472 | 476 |
| 5. Cys Pro Glu Ala Met | |
| 564 | 568 |
| 6. Phe Thr Ser Ser Thr | |

gamma chain

- | | |
|------------------------|-----|
| 301 | 305 |
| 1. Asp Lys Phe Phe Thr | |
| 343 | 347 |
| 2. His Leu Asn Gly Val | |
| 353 | 357 |
| 3. Thr Tyr Ser Lys Ala | |

Representative amino terminus antigenic peptide and probe peptide amino acid sequences are shown in the following table.

- 20 -

TABLE 4Amino Terminus Antigenic Peptides

5	A alpha chain	
	22	36
	1. Glu Arg His Gln Ser Ala Cys Lys Asp Ser Asp Trp Pro Phe Cys	
	361	375
10	2. Ser Gly Ser Thr Gly Gln Trp His Ser Glu Ser Gly Ser Phe Arg	
	451	465
	3. Ile Gly Pro Asp Gly His Lys Glu Val Thr Lys Glu Val Val Thr	
15	465	479
	4. Thr Ser Glu Asp Gly Ser Asp Cys Pro Glu Ala Met Asp Leu Gly	
	477	491
	5. Asp Leu Gly Thr Leu Ser Gly Ile Gly Thr Leu Asp Gly Phe Arg	
20	569	583
	6. Ser Tyr Asn Arg Gly Asp Ser Thr Phe Glu Ser Lys Ser Tyr Lys gamma chain	
25	306	320
	7. Ser His Asn Gly Met Gln Phe Ser Thr Trp Asp Asn Asp Asn Asp	
	348	362
	8. Tyr Tyr Gln Gly Gly Thr Tyr Ser Lys Ala Ser Thr Pro Asn Gly	
30	358	372
	9. Ser Thr Pro Asn Gly Tyr Asp Asn Gly Ile Ile (Trp)* Ala Thr (Trp)*	
	*Tentative amino acid assignment.	

- 21 -

Representative amino termini epitope amino acid sequences are shown in the following table.

TABLE 5

5

Amino Terminus Epitopes - 5 Amino Acids**A alpha chain**

22	26
1. Glu Arg His Gln Ser	
261	365
2. Ser Gly Ser Thr Gly	
451	455
3. Ile Gly Pro Asp Gly	
465	469
4. Thr Ser Glu Asp Gly	
477	481
5. Asp Leu Gly Thr Leu	
569	573
6. Ser Tyr Asn Arg Gly	

gamma chain

306	310
1. Ser His Asn Gly Met	
348	352
2. Tyr Tyr Gln Gly Gly	
358	362
3. Ser Thr Pro Asn Gly	

10 The above identified and described peptides are used as
antigens to produce antibodies which react specifically with the unique
amino acid sequence of the elastase cleavage product. The novel
peptides are also used as specific probes or antigens for determining
antiserum titer in body fluids. The various peptides can be used as
15 specificity peptides to evaluate the specificity of the unique antibodies
prepared against the various peptides.

Immunogens are prepared by attaching the individual
antigenic peptides or individual epitope peptides, or any peptide
containing said epitope onto an immunogenic carrier molecule capable of
inducing antibody synthesis in animals. An immunogen is defined herein
20 as a substance of sufficient size that when introduced into an animal
stimulates the production of antibodies reactive with the specific antigen

- 22 -

or epitope. Immunogenic carrier is defined herein as a protein or other high molecular weight compound to which an antigen or epitope is conjugated *in vitro* and which renders the antigen or epitope capable of stimulating or increasing an immune response. Peptides containing the specific amino acid epitope are termed herein antigenic peptides. Antigenic peptides include but are not limited to the peptides shown in Table 2, Table 3, Table 4 and Table 5. It is to be understood that the embodiment of this invention includes the use of the defined epitopes and antigens, without the addition of immunologic carriers or any other chemical modification, as direct stimulants of antibody formation.

The peptide antigens of the present invention may be synthesized using any suitable peptide synthesis technique, such as solid phase peptide synthesis chemistry following the method of Merrifield, *J. Am. Chem. Soc.* 85: 2149-2154. The peptides terminating in a carboxyl group are synthesized on the standard Merrifield resin. The peptides terminating in an amide group are synthesized on a 4-methyl benzhydrylamine resin. Hydrofluoric acid cleavage of the C-terminal amino acid residue from this resin yields a peptide containing an amide terminus. The procedures are known in the art. Linking amino acids such as cysteine are added, if necessary, to either the amino or carboxyl terminus of antigen peptides either during synthesis or chemically after synthesis to provide a free sulhydryl group to facilitate coupling to an immunogenic carrier. The linking amino acid is added at the opposite end of the peptide sequence from the cleavage site to allow attachment to the carrier protein leaving the proteolytic cleavage site exposed. Internal molecular markers such as norleucine may also be added during the synthesis of antigenic peptides to evaluate the number of peptide molecules bound to the carrier. Norleucine is preferred since it is not a usual amino acid component of natural proteins. The synthesized peptides are purified by preparative reverse phase high performance liquid chromatography (HPLC) with identity and purity being established by fast atom bombardment (FAB) mass spectrometry and amino acid analysis, techniques known in the art.

- 23 -

The antigenic peptides are covalently coupled to high molecular weight carrier proteins which include, but are not limited to bovine serum albumin (BSA), bovine thyroglobulin (BT), keyhole limpet hemocyanin (KLH), ovalbumin (OA), and the like, with BSA and BT being preferred. The antigenic peptides are coupled to the linking amino acid, cysteine, by maleimido-NHS-ester heterobifunctional coupling reagents which include, but are not limited to, m-Maleimidobenzoyl-N-hydroxysuccinimide ester (MSB), m-Maleimidobenzoyl-sulfosuccinimide ester (Sulfo-MBS), Succinimidyl 4-(Maleimidomethyl)-cyclohexane-1-carboxylate (SMCC) sulfosuccinimidyl 4-(N-Maleimidomethyl)cyclohexane-1-carboxylate (Sulfo-SMCC), Succinimidyl 4-(p-Maleimidophenyl) butyrate, (SMPB), sulfococinimidyl 4-(p-Maleimidophenyl) butyrate, (Sulfo-SMPB), with MBS and Sulfo-MBS being preferred. The carrier protein, generally BSA or BT, is prepared by dissolving about 10 mg in about 2.5 ml of about 100 mM phosphate (K^+) buffer at about pH 7.25. All buffers used in the coupling process must be exhaustively de-gassed prior to use. To the dissolved carrier is added about 5 mg of the coupling reagent, and the solution is stirred for 15 minutes to 30 minutes. The activated protein carrier is purified by size exclusion chromatography using Sephadex gel about G25, a PD10 pre-packed column (*Pharmacia*). The activated carrier is eluted with about 3.5 ml of about 100 mM phosphate (K^+) buffer, pH about 5.8 into about 6 micromoles of purified lyophilized peptide for carrier-peptide linking. The mixture is maintained at about 4°C overnight, and the cross-linked peptide is purified by size exclusion chromatography using Sephadex gel about G25 (*Pharmacia*) or dialysis and lyophilized.

The antigenic peptide-carrier conjugate is analyzed to determine the number of molecules of peptide bound to each molecule of carrier. A sample of peptide-carrier conjugate, about 0.5 mg, is hydrolyzed in about 1 ml of about 6.0 N HCl maintained at about 110°C, constantly boiling HCL *in vacuo* for about 24 hours. There will be one norleucine molecule in the hydrolysate for each peptide molecule bound the carrier. An adequate immunogen, containing either a 15 amino acid

- 24 -

peptide or a 5 amino acid peptide, will contain at least 5 moles of antigen peptide per mole of carrier.

Monospecific antibodies to the antigenic peptides are purified from mammalian antisera containing antibodies reactive against both the peptides and the carrier or prepared as monoclonal antibodies reactive with only the specific peptide using the technique of Kohler and Milstein. Monospecific antibody as used herein is defined as a single antibody species or multiple antibody species with homogenous binding characteristics for the relevant peptide antigen. Homogenous binding as used herein refers to the ability of the antibody species to bind to a specific antigen or epitope, such as those associated with the HLE cleavage sites of human fibrinogen, as described above. Peptide specific antibodies are raised by immunizing animals such as mice, rats, guinea pigs, rabbits, goats and horses, with rabbits and guinea pigs being preferred, with an appropriate concentration of the specific peptide-carrier complex either with or without an immune adjuvant. Preimmune serum is collected prior to the first immunization. Each animal receives between about 50 μ g and about 300 μ g of a single peptide-carrier complex associated with an acceptable immune adjuvant. Such acceptable adjuvants include, but are not limited to Freund's complete, Freund's incomplete, alum-precipitate, water in oil emulsion containing *Corynebacterium parvum* and tRNA. The initial immunization consisted of the specific peptide-carrier conjugate in, preferably, Freund's complete adjuvant at multiple sites either subcutaneously or intradermally. Each animal is bled at regular intervals, preferably weekly, to determine antibody titer. The animals may or may not receive booster injections following the initial immunization. Those animals receiving booster injections are given an equal amount of peptide-carrier conjugate in Freund's incomplete adjuvant by the same route. Booster injections are given at about three week intervals until maximal titer is obtained. At about 7 days after each booster immunization or about weekly after a single immunization, the animals are bled, the sera are collected, aliquoted and stored at about -20°C.

- 25 -

Monoclonal antibodies (mAb) reactive with the peptide antigens of human leukocyte elastase-cleaved fibrinogen, as shown in Tables 2, 3, 4 and 5, are prepared by immunizing inbred mice, preferably Balb/c mice with the appropriate peptide-conjugate. The mice are immunized by the intraperitoneal or subcutaneous route with about 0.1 mg to about 10 mg, preferably about 1 mg, of the specific antigenic peptide conjugate in about 0.5 ml buffer or saline incorporated in an equal volume of an acceptable adjuvant. Such acceptable adjuvants include, but are not limited to, Freund's complete, Freund's incomplete, alum-precipitate, water-in-oil emulsion containing *Corynebacterium parvum* and t-RNA, with Freund's incomplete adjuvant (IFA) being preferred. The mice received an initial immunization on day 0 and are rested for approximately 24 weeks. Immunized mice are given a booster immunization of about 1 mg of the conjugate or peptide in a buffer solution such as phosphate buffered saline by the intravenous route. At approximately day three after the booster immunization the mice are tested for peptide antibody. Lymphocytes, from antibody positive mice, preferably splenic lymphocytes, are obtained by removing spleens from immunized mice by standard procedures known to the art. Hybridoma cells are produced by mixing the splenic lymphocytes with an appropriate fusion partner under conditions which will allow the formation of stable hybridomas. Fusion partners may include, but are not limited to: mouse myelomas P3-NS1-Ag 4-1; MPC-11; S-194; NS.1 and Sp 2/0, with Sp 2/0 being preferred. The antibody producing cells and myeloma cells are fused in polyethylene glycol, about 1000 mol. wt., at concentrations from about 30% to about 50%. Fused hybridoma cells are selected by growth in hypoxanthine, thymidine and aminopterin supplemented Dulbecco's Modified Eagles Medium (DMEM) by procedures known in the art. Supernatants are collected from growth positive wells on about days 14, 18 and 21 and are screened for antibody production by a solid phase immunoradioassay (SPIRA) using the specific peptide antigens as the antigen. The culture supernates are also tested in the Ouchterlony precipitin assay to determine the isotype of the mAb. Cells from the antibody positive wells are cloned in soft agar by the technique of

- 26 -

MacPherson, "Soft Agar Techniques", in *Tissue Culture Methods and Applications*, Kruse and Paterson, Eds Academic Press, 1973.

Monoclonal antibodies are produced *in vivo* by injecting pristane primed BALB/c mice, approximately 0.5 ml per mouse, with about 2×10^6 to about 6×10^6 hybridoma cells, about 4 days after priming. Ascites fluid is collected at approximately 8-12 days and the monoclonal antibodies precipitated with ammonium sulfate, about 35% to about 60% of saturation, with 45% being preferred, washed and resuspended in a physiologically acceptable buffer at a pH of about 7.2. Such physiologically acceptable buffers include, but are not limited to, phosphate buffered saline, phosphate buffered saline glucose, buffered saline and the like.

In vitro production of anti-peptide mAb is carried out by growing the hybridoma in DMEM containing about 2% fetal calf serum to obtain sufficient quantities. The *in vitro* produced mAb is purified by the same procedure as that for the ascites fluid. The monoclonal antibodies are further purified by affinity chromatography using a protein A Sepharose matrix and the technique of Ey *et al.*, *Immunochemistry* 15: 429-436 (1978) for IgG antibodies or a similar technique for other antibody isotypes. The purified monoclonal antibody, is neutralized with about 1M phosphate buffer at about pH 8.0 and stored as above.

Antibody titers of animal sera or monoclonal antibodies, antibody sensitivity, antibody specificity and the presence of and concentration of unknown antigens in body fluids are determined by various serological or immunological assays including precipitation, passive agglutination, enzyme-linked immunosorbent antibody (ELISA) technique, and radioimmunoassay (RIA) with RIA being preferred. Titer is defined herein as a measure of the concentration of antibody in a serum sample. The antibody titer of a given serum sample is related to the affinity of the antibody for the antigen. A serological or immunological assay is defined as a method of determining a specific component of a mixture or a specific amount of a known substance in which specific antigens or antibodies are used for the determination. Each assay includes the appropriate controls. The RIA is carried out in an assay

- 27 -

buffer which may include, but is not limited to, buffered saline, phosphate buffer, phosphate buffered saline, Dulbecco's calcium-and magnesium-free buffered saline with Dulbecco's calcium-and-magnesium-free phosphate buffered saline (GIBCO) being preferred.

5 The assay buffer may be used alone or preferably supplemented with about 0.1% gelatin, about 0.01% thimerasol and 1.0 mM ethylene-diaminetetraacetic acid (EDTA). Antiserum or monoclonal antibodies are prepared for antibody titer determination by dilution in the assay buffer. The initial dilutions are generally 1:1,000, 1:5,000 and 1:10,000.

10 Antigenic probes useful for antibody binding and titer determination include either synthesized or native specific antigen peptides containing the specific epitope. The peptides used as antigenic probes may contain only the specific amino acid epitope sequence or the amino acid antigenic sequences as depicted in Tables 2, 3, 4 and 5, 15 modifications thereof, or they may include longer peptide units of the A alpha or gamma chain of fibrinogen which include the specific antigenic or epitope sequences and modifications. The antigenic probes may also include native peptides or synthesized peptides of as many as about 20 to about 30 amino acids but which also include the specific antigen or 20 epitope sequence. Synthesized peptide probes are produced by the Merrifield technique, *supra*. Probes are selected or designed to be easily attached to a label or a tracer such as enzymes, fluorescent dyes, radioisotopes or haptens. The tracer or label allows for quantification of the serologic reaction. Synthesized peptides are designed to contain one 25 or more additional amino acids which will allow the coupling of the label to the antigenic probe. Radioisotopes are the preferred label or tracer for the embodiments of this invention. Probe peptides are labeled with tritium (^3H), ^{14}C carbon (^{14}C), ^{125}I iodine (^{125}I) or ^{131}I , with ^{125}I being preferred. To facilitate radioiodination each synthesized peptide is 30 designed to contain one or more tyrosine residues, which may be part of the natural sequence, to allow coupling of the label to the antigenic probe. Radioiodination is accomplished using the chloramine T, iodogen or lactoperoxidase process with the chloramine T process being preferred. The labeled probed peptides are purified by reverse phase HPLC, size

- 28 -

exclusion chromatography or ion exchange chromatography with HPLC being preferred. The amount of radioactivity per peptide is determined by procedures known in the art.

The radioactive probe is diluted in assay buffer to yield
5 about 10,000 counts per minute (cpm) to about 30,000 cpm per aliquot, with about 20,000 cpm being preferred. The appropriate concentration of the specific probe is contacted with the diluted antibody. All determinations are made in duplicate. Following the contacting of the
10 diluted antibody with the labeled probe, the mixture is incubated at about 4°C for about 10 to about 20 hours. Non-antibody-bound radioactive probe is removed from the reaction mixture by chromatographic, precipitation, immunoprecipitation or adsorption techniques with
15 adsorption of the unbound probe onto dextran-coated activated charcoal being preferred. The dextran-coated charcoal is prepared by suspending activated charcoal, USP, at about 3% (w/v) in 10 mM phosphate buffer, pH 7.5, containing about 0.25% (w/v) dextran, about 60,000 to about
20 90,000 average mol. wt., with about 70,000 average mol. wt., being preferred. The dextran-charcoal mixture is allowed to stand overnight, sedimented by centrifugation, washed once in dextran-containing phosphate buffer as above and centrifuged again. The dextran-coated
25 activated charcoal is resuspended in the same buffer about to a 3% concentration. Immediately before use in the assay, the dextran-coated activated charcoal is diluted about 10-fold in Dulbecco's PBS and an amount sufficient to bind free probe is added to each sample. After a
30 brief incubation period in a slurry of ice in water, the charcoal is sedimented by centrifugation and the supernatant fluid collected and counted in a gamma counter. Each assay includes charcoal-free controls, to which about 1 ml of PBS is added, for determination of total counts, and antibody-free controls for determination of non-specific binding. Percent specific binding at each antiserum dilution is determined by subtracting the value for non-specific binding from the value of antiserum binding and then dividing by the total counts per minute.

Sensitivity of the antisera is also determined by serologic assays, with RIA being preferred. The antiserum is diluted in an

- 29 -

appropriate buffer, such as assay buffer, such that it binds about 15 percent to about 40 percent of the total radioactive probe, with about 25 percent being preferred. The same buffer is used for all dilution. The appropriate peptide antigen, complementary to the specific antibody, is
5 diluted in assay buffer to approximate concentrations to yield about 1 pmole, about 0.1 pmole and about 0.01 pmole of peptide per assay aliquot. Complementary as used herein is defined as the specific amino acid sequence of an epitope that will specifically bind to an antibody raised specifically against that epitope resulting in an antiepitope
10 antibody. The radioactive probe, ^{125}I -labeled peptide complementary to the specific antibody, is diluted in assay buffer to yield about 10,000 cpm per assay aliquot. The assay includes antibody-free samples for determination of non-specific binding, and controls containing antibody and probe without unlabeled peptide, to determine the control level of
15 probe binding. All determinations are made in duplicate.

Following the contacting of the diluted antibody with the labeled probe the mixture is incubated at about 4°C for about 10 to about 20 hours. Antibody-bound radioactive probe is removed from unbound probe by chromatographic, precipitation, immunoprecipitation of
20 adsorption techniques with adsorption of the unbound probe onto dextran-coated activated charcoal being preferred, as described above. Diluted dextran-coated activated charcoal is added to each sample. After a brief incubation period in a slurry of ice in water, the charcoal is sedimented by centrifugation and the supernatant fluid collected and
25 counted in a gamma counter. The presence of non-labeled peptide inhibits the binding of labeled probe. The inhibition increases as the concentration of non-labeled peptide increases. The extent of inhibition at each level of peptide is calculated as the percent of the specific binding observed in the absence of unlabeled peptide. The sensitivity of antisera
30 are compared by determining for each antiserum the 50% inhibitory concentration (IC_{50}) of the specific peptide and then comparing that to the value for the other sera. The IC_{50} as used herein is defined as the concentration of antigen producing 50 percent inhibition of probe binding.

- 30 -

Specificity of the individual antisera is also determined by serologic assays, with RIA being preferred, as described above. The antiserum is diluted in an appropriate buffer, such as assay buffer, to a concentration that binds about 15 percent to about 40 percent of the total radioactive probe, with about 25 percent being preferred. Various length probe peptides, which may contain at least the five amino acids adjacent to the amino or carboxyl cleavage sites of the A α or gamma chain, including as a standard the specific peptide antigen complementary to the antiserum are diluted in assay buffer to yield amounts ranging from about 10^{-13} moles to about 10^{-6} moles in the assay aliquot. Controls will include probes which do not contain the specific epitope. The radioactive probe, 125 I-labeled peptide complementary to the specific antibody is diluted in assay buffer to yield about 5,000 cpm to about 25,000 cpm with a range of about 10,000 cpm to about 20,000 cpm being preferred per assay aliquot. The volume of each reactant in an assay may range from about 1 μ l to about 1 ml, with about 100 μ g being preferred. Specificity is determined by either an equilibrium assay or a non-equilibrium assay. In an equilibrium assay the specificity probes are diluted and contacted with a constant amount of antibody and further contacted with a constant amount of complementary labeled probe and incubated for about 10 to about 20 hours. In a non-equilibrium assay the specificity probes are diluted and contacted with a constant amount of antibody and incubated for about 2 to about 20 hours. After the initial incubation, the labeled probe is added and the samples are incubated for a second time for about 30 minutes to about 4 hours. The equilibrium assay is the preferred assay. The assay includes antibody-free controls to evaluate non-specific binding and controls containing antibody and probe without unlabeled peptide to determine the control level of probe binding.

Following the contracting of the antibody and the specificity probe and the subsequent addition of the labeled probe, the mixture is incubated at about 4°C for about 10 to about 20 hours. Antibody-bound radioactive probe is separated from unbound probe by chromatographic, precipitation, immunoprecipitation or adsorption techniques, with adsorption of the unbound probe onto dextran-coated activated charcoal

- 31 -

being preferred, as described above. After a brief incubation period in a slurry of ice in water, the charcoal is sedimented by centrifugation and the supernatant fluid, containing the antibody-bound probe, is collected and counted in a gamma counter. All techniques are known to the art.

5 The control level of probe binding is determined and the extent of inhibition at each concentration of specificity probe is calculated from the percent of the specific binding observed in the absence of specificity probe. The specificity of each antiserum is measured by comparing the levels of the various specificity probes which
10 yield 50 percent inhibition of labeled probe binding. For a highly specific antiserum, much higher levels of specificity probe more than the specific one complementary to the antiserum will be required to yield 50 percent inhibition.

 The monospecific antibodies, as identified and characterized
15 above, are used to assay for the formation of the complimentary elastase cleavage product antigens or epitopes in whole blood or other body fluids, peritoneal fluid, sputum or bronchoalveolar lavage fluid. The assay for cleavage products is dependent upon the presence of leukocyte elastase in the sample. The preferred elastase is neutrophil elastase, but
20 the embodiment of the invention includes all leukocyte elastases. The elastase may be released from leukocytes present in the sample fluid, as described below, or may be added to the assay by adding viable leukocytes or by the addition leukocyte extracts or purified elastase. The disease state will generally determine what fluid samples are necessary
25 for the detection of elastase cleavage products. Blood and bronchoalveolar lavage fluid are the preferred fluids for following disease states; pulmonary emphysema, chronic bronchitis, cystic fibrosis, chronic obstructive pulmonary disease, bronchiectasis, adult respiratory distress syndrome, myelogenous leukemia and infantile respiratory
30 distress syndrome. Blood and synovial fluid are the preferred fluids for the following diseases; arthritis and gout. The fluids of choice for glomerulonephritis are blood, urine and peritoneal fluid.

 Aliquots of freshly-drawn blood or other body fluids including lavage washes which contain cells, are treated with an

- 32 -

anticoagulant. Such anticoagulants include, but are not limited to, ammonium or potassium oxalate, disodium citrate, sequestrene, fluoride and heparin, with heparin being preferred. The samples are incubated in the presence of compounds capable of perturbing the cell membranes of leukocytes resulting in the release of intracellular elastase. Perturbation as used herein is defined as a variation in or alteration of or deviation from the normal structural integrity of leukocyte cellular and vesicular membranes. Perturbating agents allow the release of intracellular enzymes, such as elastase, from intact cells by membrane alteration resulting in exocytosis or the like or my lyse the membranes and release the enzymes. Agents capable of membrane perturbation include, but are not limited to, zymosan, antigen-antibody complexes, complement C5a, N-formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP), phobol-12-myristate-13-acetate (PMA) plus cytochalasin B, n-formyl-L-norleucyl-L-leucyl-L-phenylalanine (FNLP) plus cytochalasin B and calcium ionophore A23187, platelet activating factor or any membrane perturbing agent which can alter the membranes of leukocytes resulting in the release of intracellular enzymes. The preferred agent for membrane perturbation is the calcium ionophore A23187 in concentrations ranging from about 75 μ M to about 300 μ M per aliquot. Prior to adding to the blood or body fluid, the calcium ionophore is dissolved in DMSO with the final concentration of DMSO in blood remaining constant at about 0.2%. Following incubation at about 37°C for about 25 minutes, the blood or body fluid is centrifuged at about 2,000 x g and the plasma or cell free body fluid is collected. The unique elastase cleavage products of fibrinogen in plasma or a cellular fluid can be assayed by the above procedure or the protein can be removed from the plasma by precipitation with chilled ethanol at a ratio of about 3:1 ethanol to plasma or fluid. The plasma-ethanol or fluid-ethanol mixture is centrifuged at about 3,000 x g, the supernatant fluid collected and evaporated to dryness in a Speed-vac concentrator. The treated plasma or fluid is reconstituted to original volume with distilled water and samples are assayed for the presence of the unique elastase cleavage products of fibrinogen by an assay procedure capable of detecting the specific antigens or epitopes. As the

- 33 -

concentration of calcium ionophore A23187 increases the amount of cleavage product increases until it reaches a maximum at an ionophore concentration of about 150 μ M.

5 Fluid samples which do not contain neutrophils can also be assayed in a similar manner. These samples may be treated with a standard concentration of neutrophils and then treated with a perturbing agent or they may be treated with a standard amount of purified elastase. The fluids, cells and elastase in most situations would be homologous.

10 Elastase cleavage products can be identified and the concentration determined by a variety of immunoassays, which include but are not limited to: immunoradiometric assays, employing labeled antibodies, Miles and Hales, *Nature* 219: 186- (1968) or a sandwich variant according to Addison and Hales, *Hormone Meta. Res.* 3: 59- (1971); enzyme immunoassays, employing competitive assays with
15 antigen-enzyme conjugates according to the method of Van Weeman and Schours, *F.E.B.S. Lett.* 15: 232- (1971) or enzyme-labeled antibody assays according to the procedure of Envall and Perlmann, *Immunochem.* 8: 871- (1971) or a variant of the enzyme-labeled antibody assay which employs detection by a second antibody according to the process of
20 Hammarstrom *et al.*, *Proc. Natl. Acad. Sci. USA* 72: 1528- (1975) or non-competitive sandwich (ELISA) methods, see Nakamura *et al.*, in *Handbook of Experimental Immunology, Vol. 1, "Immunochemistry"*, D. M. Weir, ed. 4th Edition (1986), Blackwell Scientific Publications, Oxford, pp. 27.1-27.20: or labeled antigen (RIA) as described above or
25 any other assay which will determine antigen concentration. The preferred assay is the RIA as generally described above and in more detail hereinafter. The total volume of the assay fluid may range from about 5 μ l to about 1 ml with about 100 μ l to about 500 μ l being preferred. Standard solutions or known or unknown cleavage products
30 are prepared assay buffer, as described above, in the range of about 1×10^{-10} M to about 2×10^{-8} M which represents amounts of peptide ranging from about 0.01 picomoles to about 2.0 picomoles in an appropriate volume, about 100 μ l of buffer. The standard solutions or dilutions of unknown samples are contacted with an antibody solution.

- 34 -

The antibody solution may contain one or more monospecific antibodies specifically reactive with the antigens listed in Tables 2, 3, 4 and 5 or antibodies reactive with any epitope listed in the Tables on any length fragment of fibrinogen. The antibody solution is generally at a concentration sufficient to give a positive reaction, usually about a 1:1000 dilution of serum in an appropriate buffer such as assay buffer. The samples containing antigen and antibody are mixed and a labeled probe complementary to the specific antibody or antibodies is added. A radioactive probe or probes will be diluted in an appropriate buffer, assay buffer, to yield about 10,000 to about 25,000 cpm per about 100 μ l of buffer. Each assay includes antibody-free controls to measure non-specific binding and controls containing antibody plus probe without added standard or unknown to determine the control level of peptide binding.

Following the contacting of the diluted antibody with the labeled probe, the mixture is incubated at about 4°C for about 10 to about 20 hours or at about 37°C for about 10 minutes to about 2 hours. Antibody-bound radioactive probe is separated from unbound radioactive probe by chromatographic, precipitation, immunoprecipitation or adsorption techniques with adsorption of the unbound probe onto dextran-coated activated charcoal being preferred, as described above. Diluted dextran-coated activated charcoal is added to each sample. After a brief incubation period in a slurry of ice in water, the charcoal is sedimented by centrifugation and the supernatant fluid collected and counted in a gamma counter. Each assay includes charcoal-free controls for determination of total counts and antibody-free controls for determination of non-specific binding. The antibody-free control and the zero-peptide antibody control are counted in a gamma counter to determine the 0% bound and 100% bound values respectively. The assay standards are counted and related to the antibody control to determine the percent probe bound, and a standard curve is generated. When the percent bound is plotted as a function of the logarithm of the amount of peptide in the standard, a sigmoidal curve is generated which is close to linear between the limits of about 80% of control to about 20% of

- 35 -

control. Unknowns are counted, their percent of control calculated, and they are compared to the standard curve to determine the amount of peptide present in the sample. Only those unknowns counting between about 80% and about 20% of control binding are considered valid.

5 The above defined assay technology is used to monitor the activity of human elastase inhibitors of human leukocyte elastase activity in human and primate blood. Generally an elastase inhibitor is combined with whole blood or given to primates or humans and the effect of leukocyte elastase on fibrinogen is determined. Replicate aliquots of
10 freshly-drawn heparinized whole human blood are prepared with concentrations of elastase inhibitor ranging up to about 300 $\mu\text{g/ml}$. Following a brief pre-incubation with the incubator, a membrane perturbator, such as calcium ionophore A23187, is added at a concentration of between about 75 μM and about 300 μM . Non-
15 membrane perturbator controls containing blood and perturbator-only controls are included to measure the extent of uninhibited peptide generation. All assay samples are incubated at about 37°C for about 25 minutes. The plasma is then prepared and assayed fibrinogen cleavage products as described above. Elastase inhibitors are capable of inhibiting
20 the generation of fibrinogen cleavage products and the levels of inhibition are easily detected using this novel assay system.

In vivo inhibition of fibrinogen cleavage products following treatment of primates with an elastase inhibitor is evaluated. Blood or
25 fluid samples are collected both before and after treatment with either an elastase inhibitor or saline. Each heparinized blood sample is divided into about 4 aliquots (about 1 ml) and processed as described above. Treatment of an animal with an elastase inhibitor causes a marked reduction in the amount of elastase cleavage product produced.

30 The ability of the novel assay to determine the presence of the unique fibrinogen cleavage products and to determine the relative amounts of these products is evaluated with blood from individuals genetically deficient in alpha 1-proteinase inhibitor ($\alpha 1\text{Pi}$), a normal serum elastase inhibitor. Individuals deficient in $\alpha 1\text{Pi}$, exhibit the PiZZ phenotype, and produce less than normal levels of circulating $\alpha 1\text{Pi}$ which

- 36 -

is a natural inhibitor of leukocyte elastase, Janoff, *Am. Rev. Respir. Dis.* 132: 417-433 (1985). Consequently individuals exhibiting the PiZZ phenotype would not have the capacity to inhibit elastase activity and they should have increased fibrinogen cleavage products when assayed
5 by the above procedure. When heparinized blood is collected from individuals who possess the PiZZ phenotype and processed as described above and levels of specific cleavage peptide antigen are measured, they are higher than normal volunteers.

The components of the assay described herein can easily be
10 assembled into a package or kit. For example, the components can be used to coat the surface of a substratum or solid carrier. Suitable carrier materials include cellulose, cross linked dextrose, silicone rubber, microcrystalline glass, and a wide variety of plastics. The most common
15 types of carriers or substratum are plastics including but not limited to polyethylene, polyvinyl chloride, polyamides, polystyrene, polypropylene and other polymers. The carrier or substratum can be formed into various shapes including but not limited to tubes, dishes, plates, multiwell plates, beads or any vessel. The assay components may be covalently bonded to the carrier or substratum, cross-linked, or physically coupled thereto. A
20 variety of detection techniques may be utilized in the assay kit of the present invention, including but not limited to, a colorimetric detection, fluorescence detection, ultraviolet radiation detection, and isotope detection. Kits suitable for immunodiagnosis, or for any other purpose described herein containing the appropriate reagents are constructed by
25 packaging the appropriate materials, including the antibodies of the present invention, in a suitable container along with the remaining reagents and materials required for the assay. A set of instruction should be included.

The following examples illustrate the present invention
30 without, however, limiting the same hereto.

- 37 -

EXAMPLE 1**Primary Cleavage of Human Fibrinogen By Human Leukocyte Elastase**

5 Purified human fibrinogen (Sigma) was combined with human neutrophil elastase (Elastin Products), at the ratio of 200 moles fibrinogen/mole human neutrophil elastase in Tris-buffer, pH 7.0 in a final volume of 1.0 ml. Samples of the reaction mixture were incubated at 37° for 5, 15, 30, 45 and 60 minutes. The reaction was stopped by the
10 addition of 3 volumes of ice-cold ethanol (3°C) incubated at that temperature for 30 minutes. Following incubation the samples were centrifuged at 3,000 x g at 3°C for 20 minutes, the supernatant fluid was removed and placed in clean tubes and the samples concentrated to dryness in a Speed-Vac overnight. Each sample was reconstituted in high
15 performance liquid chromatography HPLC buffer consisting of a mixture of water and acetonitrile and chromatographed on a Dupont-Zorbax™ C-18 column (0.4 x 25 cm). A linear gradient was developed over a 75 minute interval in H₂O:acetonitrile:trifluoroacetic acid, 95:5:0.2 v/v/v, to H₂O:acetonitrile:trifluoroacetic acid, 60:40:0.2 v/v/v. peptide peaks
20 emerging from the column were collected, rechromatographed to prove purity and subjected to N-terminal amino acid sequence analysis on an Applied Biosystems Protein Peptide Sequencer, Model 470A, following the manufacturer's procedures.

25 A 15 minute incubation time allowed the best resolution of fibrinogen cleavage products. Eight major peaks and nineteen minor peaks were identified. The major peaks represent the primary cleavage products and the minor peaks represent the minor or secondary cleavage sites. Amino acid sequence analysis of the major peptide peaks allowed the identification of nine elastase cleavage sites in human fibrinogen. Six
30 of the cleavage sites reside in the A alpha chain while three sites are located in the gamma chain, see Table 1.

- 38 -

EXAMPLE 2Synthetic Peptide Antigens

5 Knowing the specific elastase cleavage sites on both the A
alpha and gamma chain of human fibrinogen allowed the identification of
antigenic peptides and peptide probes representing the amino and
carboxyl termini adjacent to the cleavage sites. The specific amino acid
sequences associated with carboxyl termini are illustrated in Tables 2 and
10 3 while the sequences associated with the amino termini are illustrated in
Tables 4 and 5.

 Peptide antigens and peptide probes were synthesized using
t-Boc chemistry on a SAM TWO Peptide Synthesizer (Biosearch, Inc.)
and an Applied Biosystems (Model 430) peptide synthesizer. The
15 peptides terminating in a carboxyl group were synthesized on the
standard Merrifield resin. The synthesis procedure is described in detail
in the SAM TWO Peptide Synthesizer Operator's Manual (Biosearch,
1985). Cleavage of the peptide from the resin was accomplished by
treatment with hydrogen fluoride in a Protein Research Foundation
20 hydrogen fluoride apparatus following procedures outlined in the SAM
TWO Operator's Manual. Correct molecular ions were obtained by fast
atom bombardment spectral analysis for each peptide. The peptides were
purified by HPLC using an alkyl silane substrate with 18 carbon atoms
(C18) as described in the SAM TWO Operator's Manual. Purity of the
25 individual peptides was assessed by reversed phase HPLC and amino
acid analysis, again following set procedures as described in the SAM
TWO Operator's Manual. Correct molecular ions were obtained by fast
atom bombardment mass spectral analysis for each peptide. The primary
antigen associated with the carboxyl terminus for the Val (21) Glu (22),
30 see Table 1, elastase cleavage site of the A alpha chain, Gly (17)-Pro-
Arg-Val-Val (21), is synthesized with two additional amino acid residues.
The cysteine-norleucine is attached to the A α 17-21 antigen to give the
following antigen: Cys-Nle-Gly-Pro-Arg-Val-Val. The integrity of the
carboxyl group on the terminal valine residue was unaltered. The

- 39 -

cysteine is a linking amino acid because it allows the antigen to be linked or attached to an immunogenic carrier. The norleucine was added as an internal marker to determine the actual number of antigen molecules attached to a single immunogenic carrier. The 360 immunogen has the following sequence: Cys-Nle-(355)Thr-Ser-Glu-Ser-Ser-Val(360).

EXAMPLE 3

Attachment of Antigen to Carrier

Attachment of the antigenic peptides of Example 2 to the carrier protein was carried out according to a modification of the method of Lerner *et al.*, *Proc. Nat. Acad. Sci. USA* 78: 3403-3407 (1981) using either of the heterobifunctional coupling reagents, MBS or Sulfo-MBS (Price Chemical Co.). The peptide antigen is attached to the carrier bovine serum albumin (BSA), by combining 10 mg BSA dissolved in 2.5 ml phosphate buffer, 20 mM, pH 7.0 with 4.2 mg Sulfo-MBS and incubating for 30 minutes at room temperature with stirring. The A α 360 immunogen was coupled to thyroglobulin. The carrier-coupling reagent mixture was then applied to a PD-10 disposable Sephadex G-25 column (*Pharmacia*) which had been equilibrated with de-gassed 50 mM phosphate buffer, pH 6.0. The material which eluted from the column during sample application corresponded to the void volume of the column and was discarded. A small vial containing 6 micromoles of the purified, lyophilized peptide antigen was placed under the column outlet and the activated albumin was eluted into the vial with an additional 3.5 ml of the pH 6.0 buffer. The peptide antigen-activated carrier complex was allowed to react overnight. The antigen-carrier complex was purified by a second gel filtration as previously described, dialyzed against three changes of distilled water and lyophilized.

The degree of coupling was determined by amino acid analysis following hydrolysis of 0.5 mg of the lyophilized conjugate in 1 ml of 6.0 N HCl maintained at 110°C for 24 hours. The sample was

- 40 -

subjected to amino acid analysis with ninhydrin detection. The analysis showed that there were 11 moles of antigen peptide per mole of BSA.

EXAMPLE 4

5

Production of Monospecific Antibody

New Zealand White Rabbits and Hartley outbred guinea pigs were immunized with the immunogen of Example 3. Multiple
10 intradermal (ID) injections based on the method described by Vituakaitis, *Meth. Enzymol.* 73: 46-52 (1981) were employed. The initial immunizations employed 1 mg of the immunogen conjugate per ml saline homogenized with 1 ml Freund's Complete adjuvant. Rabbits received a total of 2 ml divided over 20 ID sites while guinea pigs received 1 ml.
15 Animals were boosted 30 days later. Rabbits received 0.5 mg immunogen per ml saline, homogenized with 1 ml Freund's Incomplete adjuvant while guinea pigs received 0.25 mg immunogen. The boost was divided between an intramuscular and subcutaneous site. Frequent analytical bleeds were taken in order to assess the titer and sensitivity of
20 the antisera. The antibody titer was allowed to fall almost to basal levels before re-boosting. Ten days after the final booster immunization, the animals were bled, the serum was collected and the serum was frozen and stored at -70°C.

25

EXAMPLE 5

Synthetic Probes

Antigen probes to determine antibody specificity and to
30 evaluate the presence of and amounts of fibrinogen cleavage products were synthesized by the process of Example 2. Antigenic probes used to determine the presence of and amounts of cleavage products were designed to include a tyrosine residue at the terminus distal to the epitope so that the probe could be coupled to ¹²⁵I. The initial probe used to

- 41 -

determine antibody titer consisted of the first 21 amino acids of the A alpha chain plus an amino terminal tyrosine residue.

1
5 H₂N-Tyr-Ala-Asp-Ser-Gly-Glu-Gly-Asp-Phe-Leu-Ala-Glu-Gly-Gly-
21
Gly-Val-Arg-Gly-Pro-Arg-Val-Val-COOH

Specificity probes used to evaluate antibody specificity and
10 to demonstrate that specificity resided in the Aα 17 to 21 amino acid
sequence included the following:

1
15 H₂N-Ala-Asp-Ser-Gly-Glu-Gly-Asp-Phe-Leu-Ala-Glu-Gly-Gly-
21
Gly-Val-Arg-Gly-Pro-Arg-Val-Val-COOH

5
20 H₂N-Glu-Gly-Asp-Phe-Leu-Ala-Glu-Gly-Gly-Gly-Val-Arg-Gly-Pro-
21
Arg-Val-Val-COOH

9 21
25 H₂N-Leu-Ala-Glu-Gly-Gly-Gly-Val-Arg-Gly-Pro-Arg-Val-Val-COOH

12 21
H₂N-Gly-Gly-Gly-Val-Arg-Gly-Pro-Arg-Val-Val-COOH

14 21
30 H₂N-Gly-Val-Arg-Gly-Pro-Arg-Val-Val-COOH

15 21
H₂N-Val-Arg-Gly-Pro-Arg-Val-Val-COOH

- 42 -



- $$\begin{array}{ccc} & 1 & \\ 5 & \text{H}_2\text{N-Ala-Asp-Ser-Gly-Glu-Gly-Asp-Phe-Leu-Ala-Glu-Gly-Gly-} & \\ & & 22 \\ & \text{Gly-Val-Arg-Gly-Pro-Arg-Val-Val-Glu-COOH} \end{array}$$
- $$\begin{array}{ccc} & 1 & \\ 10 & \text{H}_2\text{N-Ala-Asp-Ser-Gly-Glu-Gly-Asp-Phe-Leu-Ala-Glu-Gly-Gly-} & \\ & & 20 \\ & \text{Gly-Val-Arg-Gly-Pro-Arg-Val-COOH} \end{array}$$
- $$\begin{array}{ccc} & 1 & \\ 15 & \text{H}_2\text{N-Ala-Asp-Ser-Gly-Glu-Gly-Asp-Phe-Leu-Ala-Glu-Gly-Gly-} & \\ & & 19 \\ & \text{Gly-Val-Arg-Gly-Pro-Arg-COOH} \end{array}$$
- $$\begin{array}{ccc} & 1 & \\ 20 & \text{H}_2\text{N-Ala-Asp-Ser-Gly-Glu-Gly-Asp-Phe-Leu-Ala-Glu-Gly-Gly-} & \\ & & 18 \\ & \text{Gly-Val-Arg-Gly-Pro-COOH} \end{array}$$
- $$\begin{array}{ccc} & 1 & \\ 25 & \text{H}_2\text{N-Ala-Asp-Ser-Gly-Glu-Gly-Asp-Phe-Leu-Ala-Glu-Gly-Gly-} & \\ & & 16 \\ & \text{Gly-Val-Arg-COOH} \end{array}$$

- Radioiodination of the assay probe was accomplished by reaction with chloramine T. The peptide probe was dissolved in water at a concentration of 220 $\mu\text{g/ml}$. A 50 μl , volume of this solution (containing 11 μg) was added to 10 μl of 0.5 M phosphate (K^+) buffer and then combined with 2 mCi of ^{125}I Na and 10 μl (0.1 mg/ml) freshly prepared chloramine T in water. The mixture was allowed to react for 30

- 43 -

seconds and the reaction was stopped with 10 μ l of 1 mg/ml NaI plus 1 mg/ml sodium thiosulfate. The radioiodinated probe was purified by HPLC using a Supelco C-8 column (0.4 X 25 cm). The iodinated probe was eluted by a 30 minute 2% per-minute gradient of 90% eluant A-10% eluant B to 30% eluant A-70% eluant B at a flow rate of 1 ml per minute. Eluant A consisted of 0.1% trifluoroacetic acid in water and eluant B consisted of 0.1% trifluoroacetic acid in acetonitrile.

EXAMPLE 6

10

General Immunoassay Protocol

The assay was conducted in a total volume of 300 μ l of Dulbecco's calcium-and-magnesium-free phosphate buffered saline supplemented with 0.1% gelatin, 0.01% thimerosal and 1.0 mM EDTA. To 100 μ l of buffer or sample were added 100 μ l each of antiserum and radioactive probe diluted in the same buffer. The dilution of radioactive probe was prepared such that 15,000 to 20,000 cpm are added to each sample or control. The assay was incubated overnight at 4°C and terminated by the addition of 0.3% dextran-coated charcoal. After sedimentation of the charcoal by centrifugation, the supernatant fluid was decanted and the amount of radioactivity determined.

Antiserum titers were determined in this protocol by varying the dilution of the antiserum added in the 100 μ l volume. The antibody dilution used in competition experiments was selected to yield approximately 30% binding of the radioactive probe. Antibody sensitivities were determined using samples containing different known amounts of the A α 1-21 peptide. Specificities were determined by comparing the displacement curve generated by A α 1-21 peptide to those generated by putative crossreactive peptides. The concentration of peptide in unknown samples was determined by relating the percent of control antibody binding of probe obtained in the presence of sample to a standard curve generated using known concentrations of peptide.

- 44 -

EXAMPLE 7

Determination of Antibody Binding

- 5 The antibody titer for the most active rabbit antisera, Example 4, against the peptide antigen of Example 1 were determined using a radioimmunoassay. The antisera were diluted in assay buffer, see Example 6, with dilutions ranging from 1:3,000 to 1:30,000 per 100 μ l. The diluted antibody was contacted with A α 1-21 radiolabeled probe, see
- 10 Example 3, containing the appropriate antigenic peptide sequence, Gly-Pro-Arg-Val-Val, 100 μ l. The radioactive probe was diluted in assay buffer to yield approximately 13,000 cpm per 100 μ l aliquot. The assay volume was made up to 300 μ l by the addition of 100 μ l assay buffer. All determinations were made in duplicate.
- 15 After overnight incubation of 4°C, antibody-bound and unbound radioactive probe were separated by adsorption of the unbound probe onto dextran-coated charcoal. Dextran-coated charcoal was prepared by suspending activated charcoal, USP, at a 3%, w/v, concentration in 10 mM phosphate buffer, pH 7.5, containing 0.25%,
- 20 w/v, T-70 dextran, 70,000 average molecular weight (*Pharmacia*). The mixture was allowed to stand overnight was sedimented by centrifugation, washed once in dextran-containing phosphate buffer as above, and was then resuspended to a 3% concentration in the dextran-containing assay buffer. Immediately prior to use in the assay, the
- 25 dextran-coated charcoal was diluted 10-fold in Dulbecco's PBS and 1 ml is added to each assay tube. After an incubation period of 30 minutes in an ice/water slurry, the charcoal was sedimented by centrifugation at 3,000 x g for 10 minutes and the supernatant fluid was decanted and counted in a gamma counter. The assay included charcoal-free controls,
- 30 to which 1 ml PBS was added, for determination of total counts and antibody-free controls for determination of non-specific binding. The percent specific binding at each antiserum dilution was determined by subtracting the antibody-free, or non-specific binding value from each

- 45 -

value for antibody binding, and dividing that by the total counts in the system. The results are shown in the following table.

TABLE 6

5

Percent Specific Antibody Binding

Antiserum Dilution	¹²⁵ I-CPM	Percent Specific Binding
3,000	3,700	
	3,828	26.5
15,000	1,134	
	1,109	6.5
30,000	717	
	787	3.7
Total	12,980	
	13,454	--
Non-specific	243	
	273	--

10 Rabbit antiserum designated number 20, at a final dilution of 1:3000 binds 26 percent of the total radioactive probe. This antibody concentration is more than sufficient for determining the presence of specific cleavage peptide.

EXAMPLE 8

15

Determination of Antibody Sensitivity

20 Antibody sensitivity was determined by evaluating the ability of various concentrations of unlabeled probe to inhibit binding to the radioactively labeled probe. The antiserum, Example 4, was diluted in the assay buffer, Example 6, to a concentration of 1:1,000 and 100 μ l was used in each sample of the assay. The unlabeled probe, A α 1-21, was diluted in assay buffer to give final concentrations of 1.0, 0.1, 0.01 picomoles per 100 μ l. The radioactive probe ¹²⁵I-tyrosyl-A α 1-21 was

- 46 -

- diluted in assay buffer to yield approximately 10,000 cpm per 100 μ l. The assay was set up in a total volume of 300 μ l, with the volume made up where necessary with assay buffer. The assay included antibody-free controls to determine non-specific binding and controls containing
- 5 antibody plus probe, without added specificity probe to determine the control level of probe binding. All determinations were made in duplicate. The assay samples and controls were processed and counted as described in Example 7. Percent control binding was determined by
- 10 calculating the average cpm for the duplicate samples at each concentration of specificity probe, subtracting the average non-specific binding cpm, and dividing the results by the antibody-only counts. The results are shown in the following table.

TABLE 7

15

Sensitivity of Antibody

Sample	¹²⁵ I-CPM	Percent Control Binding
Amount of Unlabeled Probe (pmole)		
1.0	402	
	416	10.5
0.1 and	1,383	
	1,393	57.1
0.01	2,243	
	2,158	95.8
Antibody only	2,186	
	2,390	
Non-specific	193	---
	185	
Total cpm	9,564	---
	9,498	

- 47 -

The sensitivity assay shows that the amount of A α 1-21 peptide capable of inhibiting the binding of radiolabeled probe by 50 percent is approximately 0.1 picomole.

5

EXAMPLE 9

Determination of Antibody Specificity

Antibody specificity was determined by evaluating the ability of unlabeled peptides, specificity probes, of varying length, see Example 6, to inhibit the binding of the A α 1-21 radioactive probe. Rabbit antiserum prepared against the A α 17-21 immunogen described in Example 2 was diluted in assay buffer, see Example 6, at a dilution of 1:1,000. The specificity peptides of Example 5 were diluted in assay buffer at concentrations ranging from 1.6×10^{-10} M to 1×10^{-5} M. One hundred μ l of each dilution was added to 100 μ l of antiserum and 100 μ l of radioactive probe. This represents specificity probe peptide in concentrations ranging from 0.016 picomoles to 1.0 nanomoles in the 100 μ l aliquot used in the assay. The radioactive probe 125 I-tyrosyl-A α 1-21, see Example 5, was diluted in assay buffer to yield approximately 20,000 cpm per 100 μ l aliquot, the amount used per sample or control. The assay was set up in a volume of 300 μ l, with the volume made up where necessary with assay buffer. The assay included antibody-free controls used to determine non-specific binding and controls containing antibody plus probe to determine the control level of probe binding. All determinations were made in duplicate. After overnight incubation at 4°C, non-antibody-bound radioactive probe was separated from antibody-bound radioactive probe by adsorption onto dextran-coated activated charcoal as described in Example 7. The assay included charcoal-free control, to which 1 ml of PBS was added, for the determination of total counts.

The antibody-free control and the zero-peptide antibody control are counted to determine the 0% bound and the 100% bound values respectively. Radioactivity was determined using a gamma

- 48 -

counter and standard techniques known in the art. The samples containing the test peptides are then counted and the amount of radioactivity associated with the antibody-free control subtracted from each. The resulting net counts are divided by the net counts in the antibody-only control to determine the percent bound in the presence of each amount of peptide. The following table shows the amount of each specificity probe necessary to inhibit antibody binding of labeled probe by 50 percent.

10

TABLE 8Antibody Specificity

Specificity Probe	Inhibitory Concentration (IC50) picomoles	
	Rabbit (#20)	Guinea Pig (#3)
A α 1-21	0.1	0.1
A α 2-21	0.1	--
A α 9-21	0.1	--
A α 12-21	0.1	--
A α 14-21	0.2	--
A α 15-21	0.2	--
A α 17-21	1.6	10
A α 17-21-NH ₂	> 1000.0	5000
A α 1-22	> 1000.0	--
A α 1-20	600.0	--
A α 1-19	800.0	--
A α 1-18	> 1000.0	--

15

The table lists the amount of each peptide required to inhibit radioactive probe binding by 50 percent, the inhibitory concentration. Only those specificity peptides which have the entire A α 17-21 carboxyl

- 49 -

sequence cross-react with the labeled probe A α 1-21. It should be noted that the amidated analog of A α 17-21 is not cross-reactive.

EXAMPLE 10

5

Immunoassay Protocol for the Determination of A α 17-21 Epitope Containing Peptide Concentration In Unknown Samples

The radioimmunoassay was conducted in a total volume of 300 μ l with all dilutions carried out in assay buffer, Example 6. Standard solutions were prepared at concentrations in the range of 1×10^{-10} M to 2×10^{-8} M which represents amounts of peptide ranging from 0.01 picomoles to 2.0 picomoles in the 100 μ l aliquot used in the assay. The assay included antibody-free controls to measure non-specific binding, and controls containing antibody and probe without added standard samples or unknown samples to determine the control level of peptide binding. To 100 μ l of buffer, standard sample or unknown was added, 100 μ l of specific antiserum from Example 2 and 7, diluted 1:1,000 in assay buffer. This was followed by the addition of 100 μ l of radioactive probe, 125 I-Tyrosyl-A α 1-21 fibrinogen peptide, diluted in assay buffer to yield approximately 15,000 to 20,000 cpm per 100 μ l aliquot. The assay was incubated overnight at 4°C and the non-antibody-bound radioactive probe was separated from antibody-bound probe by adsorption onto dextran-coated activated charcoal, see Example 7. Each assay included charcoal-free controls, to which 1 ml PBS was added for the determination of total counts. Radioactivity was determined using a gamma counter and standard techniques known in the art.

The antibody-free control and the zero-peptide antibody control were counted to determine the 0% bound and 100% bound values respectively. The assay standards are then counted and divided by the antibody control to determine the percent bound and a standard curve was generated. When the percent bound is plotted as a function of the logarithm of the amount of peptide in the standard, a sigmoidal curve is generated which is close to linear between the limits of 80% bound and 20% bound. Unknowns are counted, their percent of control calculated

- 50 -

and they are compared to the standard curve to determine the amount of peptide present in the sample. Only those unknowns with values between 80% and 20% of control binding are considered valid.

5 ***In Vitro* Production of Cleavage Epitope Containing Peptide A α 17-21 In Human Blood. Effect of Ionophore Concentrations**

Duplicate 1.0 ml aliquots of freshly-drawn heparinized vacutainers containing 50 u per ml whole human blood were incubated for 15 minutes at 37°C in the presence of calcium ionophore A23187 at concentrations ranging up to 200 μ M. The calcium ionophore was dissolved in dimethyl sulfoxide (DMSO) with the DMSO concentration in blood kept constant at 0.2%. Following incubation the aliquots were placed on ice, centrifuged and the plasma collected. Plasma aliquots (400 μ l) were removed and placed in 12 x 75 mm glass tubes and 1200 μ l chilled ethanol was added to precipitate the protein. The sample was centrifuged and 800 μ l of the supernatant fluid was removed and evaporated to dryness in a Speed-vac concentrator. The sample was reconstituted to original plasma volume with 200 μ l of distilled water. Duplicate 100 μ l aliquots were assayed for A α 17-21 epitope containing peptide (A α 1-21) as described in this Example. The following table shows the amount of A α 17-21 epitope containing peptide produced in response to by various amounts of ionophore.

- 51 -

TABLE 9Ionophore Stimulated Production of A α 17-21 Epitope Containing Peptide From Whole Human Blood

5

Ionophore Concentration (μ M)	A α 17-21 Epitope Containing (picomoles per ml blood)
0	0
5	1.2
15	1.6
25	2.6
50	2.8
100	4.0
150	4.1
200	3.8

The optimal production of A α 17-21 epitope-containing peptide occurred following stimulation with 150 μ M of calcium ionophore A23187.

10

Ionophore Incubation Time

15

Calcium ionophore A23187 was added to replicate 1.0 ml aliquots of freshly-drawn heparinized whole blood as described above, to a final concentration of 150 μ M. Additional control aliquots of blood received DMSO at a concentration of 0.2%. The blood aliquots were incubated at 37° for various time intervals ranging up to 60 minutes. Following the incubation, plasma was prepared, processed and assayed as above. The results are shown in the following table.

- 52 -

TABLE 10

**Time dependent Production of A α 17-21 Epitope Containing Peptide
From Whole Blood By Ionophore A23187**

5

Incubation Time minutes	A α 17-21 Epitope (picomoles/ml plasma)
<1.0	0.7
2.5	2.3
7.5	2.8
10.0	3.5
15.0	3.7
20.0	3.7
25.0	3.8
30.0	3.8
40.0	3.6
50.0	3.1
60.0	3.2

10 The concentration of A α 17-21 epitope containing peptide increases with time and reaches a maximum concentration of between 3.5 and 4.0 mM between 10 and 40 minutes. Controls containing DMSO alone caused no peptide production. An incubation time of 25 minutes was selected for future experiments.

Other Membrane Perturbators

15 Other known membrane perturbators have been used to evaluate the *in vitro* production of the epitope containing cleavage peptide A α 17-21 in human blood. Aliquots of freshly-drawn heparinized whole blood were incubated for 25 minutes at 37°C in the presence of either 5 μ g/ml cytochalasin B and concentrations of phorbol-12-myristate-13-acetate (PMA) ranging up to 20 μ M or in the presence of
20 the combination of 5 μ g/ml cytochalasin B and concentrations of n-

- 53 -

formyl-L-norleucyl-L-leucyl-L-phenylalanine (FNLP) ranging up to 20 μ M. Plasma was collected, prepared and assayed as described above. The results are shown in the following tables.

5

TABLE 11

PMA And Cytochalasin B Stimulated Production of A α 17-21 Epitope Containing In Whole Human Blood

PMA μ Molar	A α 17-21 Epitope Containing Peptide Produced (picomoles/ml plasma)
0.003	0.0
0.010	0.3
0.03	0.3
0.10	0.4
0.30	0.9
1.0	1.5
3.0	2.6
10.0	3.0
20.0	3.7

10

- 54 -

TABLE 12

**FNLP And Cytochalasin B Stimulated Release of A α 17-21 Epitope
Containing Peptide From Whole Human Blood**

5

FLNP μ Molar	A α 17-21 Epitope Containing Peptide Produced (picomoles/ml plasma)
0.001	0.0
0.003	0.0
0.010	0.0
0.03	0.4
0.1	0.9
0.3	1.1
1.0	1.1
3.0	1.3
10.0	1.2
20.0	1.3

EXAMPLE 11

10 **Applications of A α 17-21 Epitope-Containing Peptide Radio-
immunoassay**

The following descriptions illustrate that the fibrinogen peptide immunoassay can be used to monitor the effective activity of human leukocyte elastase in human blood.

15

**Calcium Ionophore A23187-Stimulated Production of Fibrinogen
Cleavage Peptide in The Blood of Normal Humans**

20 Heparinized venous blood was drawn from seventeen normal healthy volunteers on three occasions over a five week period. On each occasion, calcium ionophore A23187 was added to replicate

- 55 -

aliquots of the freshly drawn blood to a final concentration of 150 μ M. The blood was incubated at 37° for 25 minutes, the plasma collected and assayed for cleavage peptide. A representative example of the results are shown in the following table.

5

TABLE 13

Calcium Ionophore A23187 Stimulation of Fibrinogen Cleavage Product
In Normal Human Blood

10

Donor	<u>Picomoles Aα 17-21</u> 10 ⁶ Neutrophils		
	Week 1	Week 3	Week 5
1	0.78	0.74	0.72
2	0.81	1.07	2.04
3	0.98	1.04	1.22
4	0.69	0.90	1.25
5	0.58	0.65	0.59
6	--	1.16	1.04
7	--	0.88	1.21
8.	--	0.62	1.10
9	--	1.12	1.07
10	0.97	1.55	0.98
11	--	0.84	--
12	--	0.55	--
13	1.40	1.23	1.00
14	1.25	0.89	--
15	1.05	1.15	1.54
16	--	1.00	1.27

Normal individuals produced consistent amounts of fibrinogen cleavage peptide as determined by this assay. The dashed

- 56 -

lines indicated that so sample was obtained from the individual at that time.

5 **Effect of An Elastase Inhibitor on Calcium Ionophore A23187-
Stimulated Production of Fibrinogen Cleavage Peptide In The Blood of
Normal Humans**

10 The effect of the elastase inhibitor 3-Acetoxymethyl-1 α -
methoxy-6-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-(2-(S)carboxy-
pyrrolidinecarboxamide)5,5-dioxide (Compound 1) on the calcium
ionophore A23187-induced fibrinogen cleavage peptide production was
evaluated. Replicate 2 ml aliquots of freshly-drawn heparinized whole
human blood were prepared with concentrations of Compound 1 ranging
up to 100 μ l/ ml. Following a brief pre-incubation of 5 minutes at 37°C,
15 calcium ionophore A23187 was added to a final concentration of 150
 μ M. Non-ionophore containing blood and ionophore-only (no inhibitor)
controls were included to measure the extent of uninhibited peptide
generation. All aliquots were incubated at 37°C for 25 minutes, the
plasma collected, processed and assayed for fibrinogen cleavage peptide
20 as described above. The results are shown in the following table.

- 57 -

TABLE 14**Elastase Inhibitor Activity Assay**

Elastase Inhibitor μg/ml	Cleavage Product Produced picomoles/ml	Percent Inhibition
0	2.4	0
1	2.3	4
5	1.6	33
10	1.6	33
20	1.5	37
30	1.2	50
40	0.8	67
80	0.4	85

5

The results demonstrate that a known elastase inhibitor is capable of inhibiting the ionophore-induced formation of the elastase cleavage product in human blood. This is consistent with the observation that exposure of whole human blood to calcium ionophore A23187 results in elastase cleavage product by allowing the release of neutrophil elastase.

10

**Effect of An Elastase Inhibitor on Calcium Ionophore A23187-
Stimulated Production of Fibrinogen Cleavage Peptide In Primate Blood**

15

Two chimpanzees were anesthetized and fitted with venous catheters for the collection of blood. Blood was collected from each animal at intervals over a 60 minute period prior to the administration of the elastase inhibitor. All blood samples were collected in heparin. After the initial 60 minute period one animal was given an intravenous injection of 10 mg/kg of the elastase inhibitor Compound 1 while the other animal received an equivalent volume of normal saline. Additional heparinized blood samples were taken from both animals at regular

20

- 58 -

5 intervals over the next 60 minutes. Each freshly-drawn sample of whole heparinized chimpanzee blood was divided into 4 aliquots. Calcium ionophore A23187 was added at a final concentration of 150 μ M to two of the aliquots and an equivalent volume of the DMSO vehicle was added to the other two. All blood samples were incubated at 37° for 25 minutes, plasma collected and assayed as described above. The results are shown in the following table.

- 59 -

TABLE 15

**Ionophore-Induced Production of A α 17-21 Epitope Containing Peptide
in Chimpanzee Blood Form An Elastase Inhibitor-Treated and Control
5 Animal**

Time (min)	A1-21 Peptide Produced (picomoles/ml plasma)	
	Treated	Control
-60.0	2.70	0.80
-45.0	3.50	1.00
-30.0	3.10	0.81
-15.0	3.00	0.95
0.0	3.00	0.98
1.0	1.10	1.20
2.5	1.30	1.10
5.0	1.60	0.97
7.5	2.00	1.10
10.0	1.80	1.20
12.5	1.70	1.10
15.0	0.98	1.50
20.0	1.90	1.50
30.0	2.20	1.20
40.0	3.10	1.50
50.0	2.60	1.20
60.0	2.50	0.96

0. Elastase inhibitor was infused into the treated animal at time

10

The blood samples drawn from the treated chimpanzee after infusion of the elastase inhibitor produced markedly lower levels of the fibrinogen peptide in response to calcium ionophore A23187. Fibrinogen

- 60 -

cleavage peptide was not detected in the non-ionophore treated blood samples from either animal. Over the course of 30 to 40 minutes, the amount of ionophore-stimulated peptide production in freshly-drawn samples gradually returned to the pretreatment level. No consistent change over time was observed in the untreated animal.

**Calcium Ionophore A23187-Stimulated Production of Fibrinogen
Cleavage Peptide in The Blood of Alpha -I Proteinase Deficient Humans**

Heparinized venous blood was drawn from four individuals who process the PiZZ phenotype, deficient for alpha-I proteinase inhibitor. Blood was also collected from two normal volunteers. Calcium ionophore A23187 was added to replicate aliquots of the freshly drawn blood to a final concentration of 150 μ M. The blood was incubated at 37° for 25 minutes, the plasma collected and assayed cleavage peptide. The results are shown in the following table.

TABLE 16

**Production of A α 17-21 Epitope Containing Peptide In Whole Blood of
PiZZ and Normal Individuals In the Presence of Calcium Ionophore**

<u>Patient</u>	<u>Control</u>	<u>A23187</u>
Normal	<0.4	4.2
Normal	<0.5	4.6
PiZZ	<0.7	8.4
PIZZ	<0.6	26.5
PIZZ	<0.5	20.5
PiZZ	<0.4	17.8

Values are expressed as pM A α 17-21 epitope containing peptide produced per ml of plasma. The blood samples derived from the four individuals who were genetically deficient in alpha-I proteinase inhibitor produced greater amounts of peptide than did those derived

- 61 -

from the normal volunteers. Under basal conditions no fibrinogen cleavage products could be detected in the blood of any of the donors.

EXAMPLE 12

5

The A α 17-21 epitope is one of several carboxyl terminus epitope peptides and antibodies to them are readily used to measure leukocyte elastase-derived fibrinogen cleavage product epitope-containing peptides in samples. Such a method may be described as follows:

10

A method for detecting leukocyte elastase-derived fibrinogen cleavage product epitope-containing peptides in body fluid samples containing leukocytes and fibrinogen, comprising the following steps:

15

a) combining the sample with an anticoagulant to form a mixture;

b) optionally, adding a leukocyte membrane perturbing agent to the mixture to release elastase from the leukocytes;

20 c) optionally, incubating the mixture under conditions that permit cleavage of the fibrinogen by the elastase to yield fibrinogen cleavage product epitope-containing peptides;

d) centrifuging the mixture to form a pellet and an epitope-containing supernatant;

e) collecting the supernatant;

25

f) adding at least one antibody to the supernatant to form an epitope-antibody mixture;

g) measuring the epitope-antibody mixture; and

h) comparing the measurement of step g) to a standard;

30

wherein the fibrinogen cleavage product epitope containing peptides are selected from the group consisting of peptides terminating in A α 17-21 residues, A α 356-360 residues, and A α 564-568 residues;

wherein the antibody is reactive with fibrinogen cleavage product epitope containing peptides selected from the group consisting of

- 62 -

peptides terminating in A alpha 17-21 residues, A alpha 355-360 residues, and A alpha 564-568-residues; and

wherein the antibody is nonreactive with uncleaved fibrinogen.

5

EXAMPLE 13

Synthesis of Peptides

10 Peptides were synthesized via the Merrifield solid-phase technique on an Applied Biosystems 430A peptide synthesizer using either tBoc or Fmoc chemistries. Using the tBoc syntheses, peptides were synthesized according to the manufacturer's recommended protocols for N-hydroxybenzotriazole ester couplings on phenylacetamidomethyl
15 resins for peptide acids. Methylbenzylhydramine resin was used for peptide amides. The peptides were deprotected and cleaved from the resin with 90% hydrofluoric acid, 10% anisole at 0°C for 1 hour and extracted from the resin with 10% acetic acid and lyophilized.

 For Fmoc synthesis, the peptides were synthesized according
20 to the manufacturer's suggested protocols for 2-(1-H-benzotriazole-1-yl)1,1,3,3,-tetramethyluronium-hexafluorophosphate mediated couplings on p-benzyloxybenzyl alcohol resins. The peptides were deprotected and cleaved from the resin with 90% trifluoroacetic acid (TFA), 5% thioanisole, 3% ethanedithiol and 2% anisole at room temperature for 2
25 hours. Crude peptides were precipitated with ethyl ether, dissolved in 10% acetic acid, lyophilized and purified by reverse phase HPLC on a Waters C18 Deltapak column. The column was eluted with a gradient of 5 to 50% acetonitrile in aqueous 0.1% TFA. All peptides were >95% pure as assessed by reverse phase HPLC on a Brownlee Spheri-ODS
30 column with a gradient of 5 to 50% acetonitrile in aqueous 0.1% TFA. Molecular ions were obtained by electrospray ionization mass spectrometry or matrix-assisted laser desorption ionization time-of-flight mass spectrometry to confirm the structure of each peptide.

- 63 -

EXAMPLE 14Immunogen/Hapten Coupling Chemistry

5 The immunogen C(Nle)T³⁵⁵SESSV³⁶⁰ synthetic peptide was coupled to bovine thyroglobulin (Sigma) by the following method. Bovine thyroglobulin (33 nmoles) was dissolved in 2.5 ml of degassed 20 mM phosphate buffer, pH 7.0, and incubated with 10 mmoles Sulfo-MBS (Pierce Chemicals) for 30 minutes at room temperature. The mixture was
10 next applied to a PD-10 column (9 ml bed volume from Pharmacia 17-0851-01) and the activated thyroglobulin was eluted with 3.5 ml of 50 mM phosphate buffer, pH 7.0 into a vial containing 6 mmoles of lyophilized peptide. This mixture was incubated overnight at 4°C with stirring. The thyroglobulin-C(Nle)T³⁵⁵SESSV³⁶⁰ immunogen was
15 separated from free unreacted peptide and reaction by-products by chromatography on a 9 ml bed volume PD-10 column eluted with PBS. The extent of peptide coupling was determined after acid hydrolysis (6 N HCl containing 0.1 % phenol at 100°C) for 24 hours followed by amino acid analysis using a Beckman Model 6300 amino acid analyzer.
20

EXAMPLE 15Production of Antiserum

25 A rabbit polyclonal antiserum, designated R-770, was raised by Research & Diagnostic Antibodies, Richmond, CA. Six New Zealand white rabbits were immunized with the thyroglobulin-C(Nle)TSESSV conjugate prepared as described above. The initial immunizations employed 1 mg of the immunogen conjugate per ml of saline
30 homogenized with 1 ml of Freund's complete adjuvant. Rabbits received a total of 0.4 ml divided between two intramuscular sites. Animals were boosted 10 days later receiving 0.5 mg immunogen per ml of saline homogenized with 1 ml Freund's incomplete adjuvant. The boost was divided between an intramuscular and a number of subcutaneous sites.

- 64 -

Thirty days later the animals were again boosted. Thereafter the rabbits were boosted every 20 days. Ten days after each boost blood was taken and sera prepared to assess the titer. The antiserum used in these studies was from rabbit 770 second bleed and designated R-770 2nd bleed. The antiserum was diluted 1:1 with glycerol and stored at -20°C. The antiserum from the terminal bleed of rabbit 770 (66 ml) showed equivalent binding and competitive dilution kinetics with the standard peptide. In addition, an antiserum (68 ml) from rabbit 3065 (R-3065 terminal bleed) showed identical binding and competitive displacement. Antisera is available for 1,224,000 assays slots.

EXAMPLE 16

Radioiodination of ^{125}I -YRGSAGHATSESSV 360 Probe

YRGSAGHATSESSV, which corresponds to residues 347 to 360 of the A α chain of human fibrinogen, was radioiodinated utilizing the iodogen method by Research & Diagnostic Antibodies (Richmond, CA). Alanine was substituted for the naturally occurring tryptophan 354 of the standard peptide to prevent oxidation. This substitution, 7 amino acids distal to valine 360 , does not impair antibody binding when compared to the binding of the natural peptide standard. Complete antibody recognition is achieved with the heptapeptide W 354 TSESSV 360 .

YRGSAGHATSESSV (0.2 nmoles) was incubated for 12-15 minutes with 400-500 mCi Na ^{125}I in an Iodogen (Pierce Chemical Co.) coated microfuge tube. The radiolabeled peptide was separated from the unreacted Na ^{125}I by chromatography on a 5 ml bed volume G-10 Sephadex column eluted with 25% acetic acid containing 0.1% Triton X-100. The non-retained material, which contained the radiolabeled peptide, was lyophilized to dryness. The ^{125}I -peptide was further purified on RP-HPLC. The peptide was reconstituted into a minimal volume of H $_2$ O and injected onto a Zorbax C8 reverse phase column and eluted with an acetonitrile/H $_2$ O gradient at 1 ml/min. Buffer A was 0.1%

- 65 -

5 TFA in H₂O and buffer B was 0.1% TFA in acetonitrile. The column was eluted for 10 min with 90% buffer A/10% buffer B; for 10 min with a linear gradient to 70% buffer A/30% buffer B; and for 30 min with 70% buffer A/30% buffer B. Fractions of 500 ml, were collected and the radioactivity determined. The fractions containing the monoiodinated peptide, usually eluting in fractions 48-52, were combined and lyophilized to dryness in serum vials. The vials were stored at -20°C until use. The final probe routinely had a specific activity of approximately 2,000 Ci/mmol.

10

EXAMPLE 17

Competitive Radioimmunoassay for A α (Val³⁶⁰)

15 A 10-X stock buffer solution containing 250 mM EDTA and 0.1% thimerosal is prepared in 1-X calcium and magnesium free Dulbecco's phosphate-buffered saline (PBS) (Gibco Cat. No. 14190-045). The RIA buffer (A α (Val³⁶⁰) PET/GEL) is prepared by diluting 100 ml of the stock solution to 1 L with H₂O and by addition of gelatin to a final concentration of 0.1% (W/V). The pH was adjusted to 7.4 \pm 0.1. The assay is conducted in a total volume of 300 μ l of this buffer. One hundred microliters of A α (Val³⁶⁰)Pet/Gel buffer or sample diluted in this buffer were mixed with 100 μ l of anti-TSESSV R-770 antiserum (final dilution 1:18,000) and 100 μ l of the ¹²⁵I-probe (~30,000 CPM) and incubated overnight at 4°C.

25 The synthetic peptide YRGSAGHWTSESSV was used to generate the standard curve. This peptide contained the natural sequence of A α (Tyr³⁴⁷-Val³⁶⁰) and differed from the ¹²⁵I-probe in which an Ala³⁵⁴ replaced Trp³⁵⁴. A 200 nM stock solution of standard peptide was prepared in A α (Val³⁶⁰) PET/GEL buffer and stored frozen at -20°C. In each experiment 12 concentration standards (0.01-20 pmoles/100 μ l) were prepared by serially diluting 100 μ l aliquots of the stock solution 1:2 in A α (Val³⁶⁰) PET/GEL buffer 11 times. Therefore, the standard curve concentrations of peptide were 0.01, 0.02, 0.04, 0.08, 0.16, 0.31, 0.625.

30

- 66 -

1.25, 2.5, 5.0, 10.0 and 20.0 pmoles/100 μ l. Tubes without standard (to measure the total amount of antiserum-binding) and tubes without antiserum (to measure the total amount of radioactivity added and background) were also included. All determinations were performed in duplicate.

The antibody-bound radiolabeled probe was separated from unbound radiolabeled material by an anti-rabbit-IgG antibody attached to magnetic beads. A suspension of BioMag beads (Goat anti-rabbit IgG (H&L) (PerSeptive Diagnostics, Cambridge MA) was diluted 1:2 just prior to use with PBS. One ml aliquots of the suspension were added to all tubes, except tubes not containing antiserum which were used for the determination of total radioactivity, and incubated at room temperature for 5 minutes. During the 5 minute incubation period, the tubes containing beads were transferred to a rack with compression springs (Amersham, Arlington Heights, IL) which securely held the test tubes. The rack was applied to a magnetic plate (Amersham, Arlington Heights, IL) and incubated for an additional 10 minutes. The rack was then inverted and the supernatant fluid containing the unbound 125 I-probe was collected in vermiculite and discarded. The ends of the tubes were blotted onto paper towels. The antiserum bound 125 I-probe peptide was "held" to the bottom of the test tube by the magnetic field.

The radioactivity associated with the 125 I-probe was determined in a 10-well Cobra II Auto Gamma Counter (Packard Instruments). The percent binding of probe to antisera (B/B_0) in the presence of the competitive unlabeled peptide was determined based on the amount bound in the absence of the competitive unlabeled peptide. The B/B_0 as a function of standard peptide concentration was plotted by a 4-parameter algorithm (Immunofit Packard Instruments). The B/B_0 of the samples was similarly determined and the concentration of the $A\alpha(\text{Val}^{360})$ neoepitope, expressed as pmoles of unlabeled peptide, was determined from the standard curve. Only values falling between 20-80% binding were considered to be valid for calculations.

- 67 -

The standard curve parameters (EC80, EC50, EC20) and the percent binding were recorded for each assay. In addition, 3 quality control standard solutions of the standard peptide (100 μ l of 2, 6 and 20 nM) were run in each assay. The quality control standards were required to be within 2 standard deviations of mean of the initial 5 assays to be considered valid.

EXAMPLE 18

10 Gel electrophoresis and Western Immunoblots

A. Sample and Standard Preparation

Samples of plasma or synovial fluids were diluted 1:10 with PBS and then 1:1 with 2X sample buffer containing 2% mercaptoethanol (NOVEX LC2676) and boiled for 5 minutes. Kaleidoscope prestained standards (Bio-Rad 161-0324) (10 ml/well) were used as received, without reduction, for alkaline phosphatase detection. For enhanced chemiluminescence (ECL) detection, biotinylated SDS-PAGE molecular weight standards (Broad Range Bio-Rad 161-0319) were diluted 1:100 in PBS, then 1:1 into 2X sample buffer and boiled for 5 minutes. Standards (10 μ l), plasma and synovial fluid samples (10-30 μ l) were routinely analyzed.

B. SDS-PAGE and Transfer Conditions

Gel electrophoresis analyses were performed using 10-lane 1 mm Tris-Glycine 4-20% gradient gels (NOVEX EC6025), Tris-glycine SDS running buffer (NOVEX 2675) in the NOVEX mini-gel system. Each well was flushed with running buffer to remove any unpolymerized acrylamide. The system was assembled and run at 4°C for 7 minutes at a potential of 100 V and then increased to 200 V for approximately 1 hour or until the sample dye-front was observed to be close to the bottom of the gel.

The gels were equilibrated for 30 minutes with Tris-glycine buffer (BioRad 161-0734) and the components electrophoretically transferred onto nitrocellulose membranes (NOVEX LC2001) using the

- 68 -

BioRad Mini Trans-Blot system as described by the manufacture. A potential of 105 V was applied for about 55 minutes or until the unit became slightly warm. The nitrocellulose membrane was placed into distilled water for a few minutes then dried and stored for subsequent immuno-blocking.

The membrane(s) were blocked for 30 minutes with 3% non-fat dried milk solution (Sigma M-7409) and then washed once in PBS containing 0.05% Tween-20 (Bio-Rad 170-6531) (PBS-T) for 10 minutes. The membrane was then incubated for 1 hour with R-770 (diluted 1:10,000 in PBS-T). The membrane was then washed 3 times for 10 minutes each with PBS-T.

C. Detection with Alkaline Phosphatase

For visualization with alkaline phosphatase, the membrane was incubated for 1 hour with anti-rabbit IgG-alkaline phosphatase conjugate (diluted 1:1,000 in PBS-T) (Sigma A-0407). The membrane(s) were then washed (3 times for 10 minutes each) with PBS alone (no Tween) and then added to the substrate solution of BCIP-NBT (Sigma B5655) prepared as described by the manufacturer (2 tablets/20 ml H₂O). After maximal color development, usually within 10 minutes, the reaction was stopped by removing the membrane to a container of 4 mM EDTA in PBS.

D. Detection with Enhanced Chemiluminescence

For detection by the enhanced chemiluminescence system (ECL) (Amersham RPN 2108) the membrane was incubated with anti-rabbit IgG peroxidase conjugate (Sigma A-4914) diluted 1:1,000 in PBS-T in combination with ExtrAvidin peroxidase (Sigma E-2886) diluted 1:5,000 to visualize the biotinylated standards.

After 1 hour the membrane was washed with PBS-T for 15 minutes followed by 2 additional 5 minute washes. The membrane was incubated for 1 minute with the 2 components of the ECL system (Amersham RPN 2108) as described by the manufacturer. The membrane was wrapped with plastic wrap and placed into a film cassette. Hyperfilm ECL film (Amersham, RPN 2114) was exposed from 10 seconds to 1 minute and developed by conventional procedures.

- 69 -

E. Digestion of Fibrinogen by Various Proteinases

Fibrinogen (Sigma Lot 117F9451) was incubated at 37°C with various serine proteinases including PMNE, PR3, plasmin, trypsin and porcine pancreatic elastase as well as with the cysteine proteinases cathepsins B, H and L at an enzyme to substrate ratio of 1:500. After 30 minutes, PMNE and PR3 activity were terminated with the monocyclic betalactam PMNE inhibitor L-680,833 (50 µM) and trypsin and porcine pancreatic elastase by PMSF (50 µM). The thiol proteinases cathepsins B, H and L were inactivated by boiling for 5 min. The amount of Aα(Val³⁶⁰) formed was determined by RIA or visualized by Western immunoblots using alkaline phosphatase detection.

F. Blood Collection

Blood was obtained by antecubital venipuncture or from the radial artery from informed adult volunteers and collected into heparin (Elkins-Sinn Inc #6505-00-153-9740), 10 units/ml. The blood was immediately mixed by inverting the tube 5 times and then placed onto a slowly rocking platform at room temperature. All experiments utilizing A23187 stimulation of blood were started within 2 hours from the time of collection.

G. Plasma Preparation

Heparinized blood (2 ml) was centrifuged at 5°C at 1800 x g for 10 min in a Beckman GS6R centrifuge. Plasma (700 µl) was removed and added to 100 µl of 250 mM EDTA and frozen (final EDTA concentration = 31 mM).

H. Synovial Fluid Collection

Synovial fluids from patients with a variety of joint diseases were collected without anticoagulant or with heparin. All samples were centrifuged and the supernatant fluids removed, frozen and stored at -70°C. In preparation for the Aα(Val³⁶⁰) analysis, the fluids were thawed and 50 µl of 250 mM EDTA added to 350 µl of the sample. The EDTA was included to inhibit endogenous proteinases which can destroy the ¹²⁵I-probe peptide.

- 70 -

I. Calcium Ionophore A23187-Stimulated Formation of A α (Val³⁶⁰) in Human Blood

Heparinized blood, 1 ml aliquots, was incubated at 37°C with 150 μ M A23187 (CalbioChem #100105), dimethylsulfoxide (DMSO) control solvent and spike recovery fibrinogen digest (FD) prepared as described below. A stock 75 mM solution of A23187 was prepared in DMSO. The A23187 solution (2 μ l of a 75 mM in DMSO), 2 μ l DMSO and 23.7 pmoles of fibrinogen digest (FD) were added to empty 2.0 ml polypropylene micro-tubes (Sarstedt #72.608) prior to the addition of 1 ml of blood. The 2 ml additions were performed with P2 or P10 Gilson Pipetman (Ranin Instruments) or with "dedicated" Hamilton syringes. The 1 ml blood additions were done with an Eppendorf repeater (Brinkmann 2226-0006) fitted with 12.5 ml Eppendorf Combitips (Brinkmann 2226-1401). After 1 hour the samples were centrifuged in a 5°C refrigerated centrifuge (Beckman) for 10 minutes at 2800 rpm. Plasma aliquots (350 μ l) were added to 50 μ l of 250 mM EDTA to achieve a final EDTA concentration of 31 mM. The samples were frozen and stored at -70°C prior to RIA analysis.

J. Preparation of A α (Val³⁶⁰) Fibrinopeptide Recovery Standard

A spike recovery standard was prepared to evaluate the stability of A α (Val³⁶⁰) neoepitope in various biological fluids and to monitor recovery throughout sample processing. Human fibrinogen (Sigma Lot 53H9320) (4,500 pmoles) was incubated at 37°C with 18 pmoles of human PMNE (substrate:enzyme ratio of 250:1) for 60 minutes. The reaction was terminated by the addition of 200 nM α_1 PI (Athens Research and Technology). The material was aliquoted into 100 μ l fractions, frozen and stored at -70°C. The concentration of PMNE generated A α (Val³⁶⁰) neoepitope was determined by RIA. The material contained essentially a single immunoreactive 42 kDa species [the predicted MW of fibrinogen A α (1-360)] reacting with the R-770 antisera, when analyzed by Western blots.

- 71 -

EXAMPLE 19

Development of an RIA for A α (Val³⁶⁰)

5 A. Generation of Antiserum

The ultimate goal of this study was to establish a direct RIA to measure the PMNE generated fibrinopeptide neoepitope A α (Val³⁶⁰). It was necessary that the antiserum should not cross react with intact fibrinogen. Also, it was important to establish which other proteinase, if
10 any, generated this neoepitope. In order to achieve such specificity, the antiserum should recognize the free carboxy group of Val³⁶⁰ which is normally in an amide linkage with Ser³⁶¹. To raise such an antiserum, C(Nle)T³⁵⁵SESSV³⁶⁰ was conjugated to thyroglobulin using the cross-linking reagent Sulfo-MBS, which specifically orients the carboxy group
15 of Val³⁶⁰ away from the thyroglobulin. The degree of peptide substitution on thyroglobulin was found to be approximately 25 moles of peptide per mole of thyroglobulin. Typically, it was necessary to incorporate at least 20 moles of a short peptide onto a carrier protein to elicit a significant antibody response in either rabbits or in guinea pigs.
20 This conjugate was then injected into rabbits.

B. Sensitivity and Reproducibility of the Assay

A number of rabbit antisera were generated and a RIA was established using an antiserum, termed R-770, at a final dilution of 1:18,000. This RIA detected the peptide antigen
25 Y³⁴⁸RGSAGHWTSESSV³⁶⁰ with a detection limit of 1.7 nM at 80% bound and 6.6 nM for 50% bound (Figure 2). Three quality control standards are included in each assay (100 μ l of 2, 6, and 20 nM standard peptide) to assess the day-to-day variability of the assay procedure. For a valid assay, the three quality control standards must be within two
30 standard deviations of the mean of the first five assays (Figure 3). This RIA possessed an inter-assay variation of 11% (N=5) with one plasma sample assayed on 5 different days giving a value of 5.1 ± 0.5 nM. An intra-assay variation of 13% (N=12) with one plasma sample yielding a value of 5.4 ± 0.7 nM when assayed in dodecaduplicate.

- 72 -

C. Specificity of the Antibody

The anti-TSESSV antiserum, R-770, possessed remarkable specificity for the free carboxy group of Val³⁶⁰. When the C-terminal Val was truncated from the sequence to generate the peptide AGHWTSESS³⁵⁹, there was no recognition by the antiserum (Figure 4). Additional C-terminal truncation peptides were prepared including AGHWTSES³⁵⁸, AGHWTSE³⁵⁷, AGHWTS³⁵⁶, and AGHWT³⁵⁵. None of these peptides were recognized by the antiserum at concentrations up to 100 μ M, confirming the requirement for the carboxy-terminal Val. A series of peptides were also prepared that extended across the PMNE cleavage site to determine if fibrinogen fragments that might be generated by cleavage distal to the Val³⁶⁰ terminal site would be recognized by the anti-TSESSV antiserum (Figure 5). There is greater than a 300 fold loss in recognition by R-770 with the peptides AGHWTSESSVS³⁶¹, AGHWTSESSVSG³⁶², AGHWTSESSVSGS³⁶³, AGHWTSESSVSGST³⁶⁴, and AGHWTSESSVSGSTG³⁶⁵, again confirming the requirement of the valine carboxyl group for recognition by R-770.

A series of peptides were synthesized to characterize the length of the peptide required for maximal recognition by the antiserum. When the sequence WTSESSV³⁶⁰ was shortened by one, two, three, or four amino acids to TSESSV, SESSV, ESSV, and SSV, there was 10, 50, 70, and 300-fold loss in recognition, respectively (Figure 6). Therefore, WTSESSV³⁶⁰ was determined to be the minimum sequence required for optimal recognition by the antiserum. Additional C-terminal substitution data are presented in Figure 7. The amidation of the ValCOOH to ValCONH₂ as well as the substitution of D-Val for the L-Val also resulted in a marked loss of recognition by the antisera. Replacement of Val with Thr or Ile resulted in a 10-100-fold loss of recognition. The replacement of Val with Leu resulted in a complete loss of recognition.

Figure 8 shows that a commercial preparation of human fibrinogen gave a 50% displacement in the RIA at 2 μ M. This slight cross-reactivity (0.1%) was immunoadsorbed with the anti-TSESSV

- 73 -

antiserum R-770. These data suggested that the A α (Val³⁶⁰) neoepitope was present in the commercial fibrinogen preparation and that R-770 does not detect intact human fibrinogen at concentrations normally found in human plasma. Additionally, Western-blot analysis data of commercial human fibrinogen confirmed the presence of a 42 kDa component, which is consistent with the predicted MW for the A α (Val³⁶⁰) neoepitope fragment. This signal was blocked by the standard peptide YRGSAGHWTSESSV³⁶⁰, but not by the spanning peptide AGHWTESSV³⁶⁰SGST. The A α (Val³⁶⁰) signal was not detected with preimmune serum (Figure 9).

D. Time-dependent Production of A α (Val³⁶⁰) by PMNE and PR3 but not by Other Proteinases

In order to determine the selectivity of PMNE to produce the A α (Val³⁶⁰) neoepitope, a series of proteinases were analyzed for their ability to hydrolyze fibrinogen at the Val³⁶⁰-Ser³⁶¹ site. PMNE, incubated at an enzyme to substrate ratio of 1:250, hydrolyzed fibrinogen to form A α (Val³⁶⁰) neoepitope in a time dependent manner (Figure 10).

Proteinase 3 (PR3) is a serine proteinase with 54% sequence homology to PMNE. It is also localized in the azurophilic granule of PMN. The incubation of fibrinogen with PR3 resulted in the time-dependent formation of A α (Val³⁶⁰) forming the neoepitope at approximately 15% of the PMNE catalyzed rate (Figure 11).

Fibrinogen was incubated at 37°C with PMNE, PR3 and other proteinases at 37° C at enzyme:substrate of 1:500 and analyzed by Western-blot (Figure 12). An intense immuno-reactive component at 42 kDa was formed by PMNE and PR3. The human serine proteinases (plasmin and trypsin) showed no additional immunostaining over the endogenous A α (Val³⁶⁰) present in the fibrinogen substrate. Likewise, the cysteine proteinases (cathepsins B, H and L) did not form the neoepitope. However, porcine pancreatic elastase showed a moderate A α (Val³⁶⁰) signal.

E. Human Plasma Degrades the ¹²⁵I-Probe Peptide

In order to validate the assay for use with biological fluids, the stability of the ¹²⁵I-probe (¹²⁵I-YRGSAGHATSESSV) in human

- 74 -

plasma was investigated (Figure 13). The incubation of the RP-HPLC purified probe with 100 μ l of human plasma for 30 minutes at 37°C resulted in the breakdown of the 125 I-probe into at least 2 new radiolabeled species as determined by subsequent HPLC analysis (Figure 13). The inclusion of EDTA (31 mM) in the incubation mixture prevented this breakdown (Figure 13). Similarly to plasma, EDTA prevented the breakdown of the 125 I-probe in incubations of various synovial fluid samples. These findings support the idea that an EDTA sensitive proteinase, such as carboxypeptidase, may remove the C-terminal Val residue from the 125 I-probe peptide and thus inhibit binding. Decreased antibody binding of the 125 I-probe peptide would appear as an artifactual positive signal in the RIA, increasing the detected neopeptide concentration above its true value.

A spike recovery standard was prepared to evaluate the stability of A α (Val³⁶⁰) in biological fluids and assess recovery throughout the sample processing protocol. A limited digest of fibrinogen (FD) was prepared using a 1:500 ratio of PMNE:fibrinogen incubated for 30 minutes at 37°C. Western immunoblot analysis showed the digest contained predominantly one immuno-reactive fragment of approximately 42 kDa (Figure 14). The concentration of A α (Val³⁶⁰) in the FD, as determined by RIA, was 0.97 μ M. Aliquots (10 μ l containing 9.7 pmoles), were added to duplicate biologic samples (ie. blood or synovial fluid) to determine recovery and stability of the A α (Val³⁶⁰) neopeptide during the RIA analysis.

Excellent recoveries of the limited fibrinogen digest were found in incubations with human blood (Table 1). When blood was incubated with A α (Val³⁶⁰) FD and 31 mM EDTA for one hour, the recovery of A α (Val³⁶⁰) FD in the plasma was 99% versus 108% when blood was incubated with FD alone. The plasma concentration of FD was corrected for the individual donor's hematocrit. However, in the absence of EDTA, it was not possible to recover the standard peptide from blood (Table 1). In the presence of 31 mM EDTA, a partial recovery (69%) was achieved. These data are consistent with the idea

- 75 -

that EDTA protects the ^{125}I -probe peptide from inactivation due to proteolysis by carboxypeptidase(s).

F. Identification of $\text{A}\alpha(\text{Val}^{360})$ Neopeptide in Control Human Plasma

RIA analysis of normal human plasma detected an endogenous $\text{A}\alpha(\text{Val}^{360})$ neopeptide in both arterial blood collected into heparin of 6.1 ± 1.1 nM (Mean \pm SD, N=10) and venous blood collected into heparin of 4.2 ± 1.5 nM (Mean \pm SD, N=13) (Table 2). Normal human plasma concentration of fibrinogen ranges from 4 to 8 μM . Therefore, the amount of the $\text{A}\alpha(\text{Val}^{360})$ neopeptide is approximately 0.1 % of the total fibrinogen pool. This is identical to the amount of $\text{A}\alpha(\text{Val}^{360})$ detected in commercial preparations of fibrinogen (Figure 8). The $\text{A}\alpha(\text{Val}^{360})$ neopeptide in plasma containing 31 mM EDTA was stable to 5 repetitive freeze/thaw cycles over a 7 day period. The mean value of 5 repetitive freeze/thaws was 5.1 ± 0.5 nM $\text{A}\alpha(\text{Val}^{360})$ (Mean \pm SD).

The existence of the endogenous plasma $\text{A}\alpha(\text{Val}^{360})$ fragment was further confirmed by Western immunoblots. An $\text{A}\alpha(\text{Val}^{360})$ immunoreactive band migrating at 42 kDa was detected in plasma from 2 normal donors when visualized by enhanced chemiluminescence (Figure 15). This signal was partially blocked by the addition of the standard peptide YRGSAGHWTSESSV (10 μM) to the R-770 antibody solution. These data are the first direct demonstration of PMNE activity in healthy individuals.

G. Production of $\text{A}\alpha(\text{Val}^{360})$ in Human Blood Stimulated by A23187 and its Inhibition by L-694,458

Figure 16 demonstrated the time-dependent production of $\text{A}\alpha(\text{Val}^{360})$ peptide in human blood stimulated with the calcium ionophore A23187 (150 μM). The maximal amount of $\text{A}\alpha(\text{Val}^{360})$ peptide was produced by within 30-60 minutes. $\text{A}\alpha(\text{Val}^{360})$ production measured by RIA was confirmed by Western blot analysis of increasing amounts of a 42 kDa peptide. Other stimuli such as zymosan and phorbol myristate acetate also gave similar results. These findings demonstrated that the cleavage of an endogenous substrate by PMNE released from PMN occurs in blood in the presence of large concentrations of the natural inhibitors $\alpha_1\text{PI}$ and α_2 -macroglobulin. Figure 17 displayed the

- 76 -

concentration dependence of the calcium ionophore A23187 to form $A\alpha(Val^{360})$ in human blood incubated at 37°C for 60 minutes. Maximal $A\alpha(Val^{360})$ peptide formation was achieved with an A23187 concentration of approximately 75 μ M. This concentration of A23187 did not cause release of lactic dehydrogenase, suggesting that PMNE was released by exocytosis in the milieu of whole blood. Routinely, 150 μ M of A23187 was used in this *ex vivo* blood assay.

The extent of $A\alpha(Val^{360})$ formation was studied in blood from different individuals. Aliquots of blood from each donor were incubated with DMSO or A23187 and the amount of $A\alpha(Val^{360})$ formed was measured by RIA (Table 3). The plasma $A\alpha(Val^{360})$ concentration in the DMSO treated blood was 4.5 ± 1.2 nM, ranging from 2.9 to 6.9 nM. The plasma concentration of $A\alpha(Val^{360})$ in blood incubated with A23187 was 33.9 ± 15.1 nM, ranging from 16.8 to 66.1 nM. After normalizing the $A\alpha(Val^{360})$ values for the number of PMN in a blood sample, DMSO treated blood contained 1.5 ± 0.5 pmoles $A\alpha(Val^{360})/1 \times 10^6$ PMN and 11.0 ± 3.7 pmoles $A\alpha(Val^{360})/1 \times 10^6$ PMN was present in blood stimulated with A23187 (Table 3). In these experiments the recovery of the fibrinogen digest was $100 \pm 21\%$.

Figure 18 demonstrated that the PMNE inhibitor L-694,458 blocked $A\alpha(Val^{360})$ peptide formation in the calcium ionophore blood assay in a concentration-dependent fashion with an EC_{50} of 0.3 μ M; complete inhibition was achieved at about 1 μ M. Normal human blood contains approximately 0.3 μ M PMNE. Thus maximal inhibition of $A\alpha(Val^{360})$ was achieved with amounts of L-694,458 which were only 3-5 times the molar excess over the total amount of PMNE present in this system. This indicates the great tropism of L-694,458 for PMNE in PMN, bearing in mind that the enzyme is present in a compartment within PMN that represents only a fraction of a percent of the total blood volume. Clearly, this *ex vivo* stimulation of human blood by A23187 to produce $A\alpha(Val^{360})$ peptide could be used to monitor the biochemical efficacy of L-694,458 following the oral administration of the drug in man.

- 77 -

H. Identification of Elevated Levels of A α (Val³⁶⁰) in Cystic Fibrosis Plasma Compared with Control Plasma

It is well documented that PMN accumulate at sites of inflammation in diseases of acute onset or in acute exacerbations of chronic inflammatory diseases. This accumulation of PMN is associated with the release of PMNE into the circulation as detected by increased levels of α_1 PI-PMNE complexes or of free enzyme in excess of natural inhibitors in the large airways in diseases such as cystic fibrosis and bronchitis. It has been difficult up to now to provide direct evidence for the activity of PMNE released during inflammation as opposed to its presence as a complex with α_1 PI.

Plasma samples from 25 patients with cystic fibrosis and from 5 normal individuals were analyzed for A α (Val³⁶⁰) obtained from Children's Hospital, Boston, Massachusetts. Figure 19 showed a clear elevation of A α (Val³⁶⁰) in the plasma of cystic fibrosis patients indicative of PMNE activity. The increases in A α (Val³⁶⁰), up to 100-fold above normal, correlated closely with increased α_1 PI:PMNE levels (R=0.99). These data are the first direct demonstration of elevated PMNE activity in disease. This assay should provide a precise indicator of the inhibition of increased PMNE activity present in the cystic fibrotic lung following drug treatment.

I. Identification of A α (Val³⁶⁰) Neoepitope in Synovial Fluids from Rheumatoid Arthritis and Gout Patients

The presence of A α (Val³⁶⁰) neoepitope was evaluated in other inflammatory diseases characterized by PMN infiltration. Elevated PMN levels are found in synovial fluid from patients with rheumatoid arthritis and gout. In contrast, joint fluids from osteoarthritis patients have few, if any, PMN and less fluid accumulation. A series of synovial fluids from various joint diseases were evaluated for the A α (Val³⁶⁰) neoepitope (Table 4). All 17 samples from RA patients contained A α (Val³⁶⁰), with values ranging from ranging from 7-88 nM. Four out of 5 samples from patients with gout also contained the A α (Val³⁶⁰) neoepitope. In contrast, A α (Val³⁶⁰) was not found in synovial fluids from 4 osteoarthritis patients. The A α (Val³⁶⁰) neoepitope was also

- 78 -

present in synovial fluids from patients with pseudogout and psoriatic arthritis. In contrast to plasma where the molecular weight of the $A\alpha(\text{Val}^{360})$ neoepitope is 42 kDa, the molecular weight of the predominant neoepitope in synovial fluid from both RA and gout patients was approximately 20 kDa, with smaller amounts of the 42 kDa component observed in some, but not all samples (Figure 20). This finding indicated that other proteinases, possible including PMNE, present in RA and gout synovial fluids may be making an additional cleavage in the fibrinogen molecule. Although the importance of PMNE in joint disease and cartilage erosion is not known, these observations suggest that measurement of $A\alpha(\text{Val}^{360})$ in synovial fluid may be a useful biochemical marker to monitor the effectiveness of an PMNE inhibitor in rheumatoid arthritis.

EXAMPLE 20

General Assay Protocol

The $A\alpha(\text{Val}^{360})$ epitope is one of the C terminus neoepitope peptides and antibodies to them are readily used to measure PMNE-derived fibrinogen cleavage neoepitopes in biologic samples. Such a method may be described as follows:

- a) combining the sample with an anticoagulant to form a mixture;
- b) optionally, adding a leukocyte membrane perturbing agent to the mixture to release PMNE from the leukocytes;
- c) optionally, incubating the mixture under conditions that permit the cleavage of fibrinogen by PMNE to yield fibrinogen cleavage product neoepitope;
- d) optionally, centrifuging the mixture to form a pellet and a neoepitope containing supernatant fluid;
- e) collecting the supernatant fluid and adding EDTA (final concentration of about 31 mM) to the supernatant fluid to form an EDTA-fluid mixture;

- 79 -

f) mixing an aliquot of the EDTA-fluid mixture with a specific antibody and ^{125}I -probe solutions;

g) separating antibody-bound probe from unbound probe and measuring the ^{125}I -probe in the antibody-bound probe fraction; and

5 h) comparing the measurement of step g to a standard.

- 80 -

WHAT IS CLAIMED IS:

1. An isolated and purified peptide comprising an epitope which includes the terminal amino acid sequence of the carboxyl terminus of the primary cleavage products of human leukocyte elastase cleaved human fibrinogen which is capable of inducing specific antibodies and acting as a specific probe for the detection of the antibodies.
 2. The purified peptide of Claim 1 wherein the peptide has an epitope selected from:

	17	21
A alpha chain amino acid residues	Gly Pro Arg Val Val;	
	356	360
A alpha chain amino acid residues	Ser Glu Ser Ser Val;	
	446	450
A alpha chain amino acid residues	Val Thr Lys Thr Val;	
	460	464
A alpha chain amino acid residues	Thr Lys Glu Val Val;	
	472	476
A alpha chain amino acid residues	Cys Pro Glu Ala Met;	
	564	568
A alpha chain amino acid residues	Phe Thr Ser Ser Thr;	
	301	305
gamma chain amino acid residues	Asp Lys Phe Phe Thr;	
	343	347
gamma chain amino acid residues	His Leu Asn Gly Val;	
	353	357
gamma chain amino acid residues	Thr Tyr Ser Lys Ala	
- or acid addition salts thereof.

- 81 -

3. The purified peptide of Claim 1 which is capable of detecting antibody to the carboxyl terminus of a primary cleavage product of human leukocyte elastase cleaved human fibrinogen, wherein the primary cleavage product is human fibrinogen A alpha chain amino acid residues Phe-Thr-Ser-Ser-Thr.

4. Isolated and purified monospecific antibodies raised against the purified peptides of Claim 1.

5. Isolated and purified specific antibodies raised against the purified peptides of Claim 2.

6. Isolated and purified monospecific antibodies raised against the purified peptide of Claim 3.

7. A method for detecting leukocyte elastase-derived fibrinogen cleavage product epitope-containing peptides in body fluid samples containing leukocytes and fibrinogen, comprising the following steps:

- a) combining the sample with an antocoagulant to form a mixture;
- b) optionally, adding a leukocyte membrane perturbing agent to the mixture to release elastase from the leukocytes;
- c) optionally, incubating the mixture under conditions that permit cleavage of the fibrinogen by the elastase to yield fibrinogen cleavage product epitope-containing peptides;
- d) centrifuging the mixture to form a pellet and an epitope-containing supernatant;
- e) collecting the supernatant;
- f) adding at least one antibody to the supernatant to form an epitope-antibody mixture;
- g) measuring the epitope-antibody mixture; and
- h) comparing the measurement of step g) to a standard;

- 82 -

wherein the fibrinogen cleavage product epitope containing peptides are selected from the group consisting of peptides terminating in A alpha 17-21 residues, A alpha 356-360 residues, and A alpha 564-568 residues;

5 wherein the antibody is reactive with fibrinogen cleavage product epitope containing peptides selected from the group consisting of peptides terminating in A alpha 17-21 residues, A alpha 3556-360 residues, and A alpha 564-568 residues; and

10 wherein the antibody is nonreactive with uncleaved fibrinogen.

8. The method of Claim 7, Step C, wherein the incubation is at about 37°C.

15 9. The method of Claim 8, Step C, wherein the incubation is for between about 10 minutes and about 40 minutes.

20 10. A method for evaluating the efficacy of inhibitors of human leukocyte elastase activity comprising treating a patient with at least one inhibitor of leukocyte elastase and using the method of Claim 7 to measure leukocyte elastase-induced fibrinogen cleavage product epitope containing peptides in body fluids of the patient.

25 11. A method for detecting leukocyte elastase-induced fibrinogen cleavage product epitope-containing peptides in body fluid samples which contain fibrinogen but which do not contain leukocytes or leukocyte elastase, comprising:

30 a) adding leukocytes or leukocyte elastase to the sample;
and
b) processing the sample according to the method of Claim 7.


12. A method of measuring polymorphonuclear leukocyte elastase activity in biological fluids comprising the measurement of

- 83 -

measurement of human fibrinogen A α (Val³⁶⁰-Ser³⁶¹) cleavage products in the sample.

13. The method of Claim 12 which comprises:
- 5 a) combining the sample with an anticoagulant to form a mixture;
 - b) optionally, adding a leukocyte membrane perturbing agent to the mixture to release PMNE from the leukocytes;
 - c) optionally, incubating the mixture under conditions that
10 permit the cleavage of fibrinogen by PMNE to yield fibrinogen cleavage product neoepitope;
 - d) optionally, centrifuging the mixture to form a pellet and a neoepitope containing supernatant fluid;
 - e) collecting the supernatant fluid and adding EDTA (final
15 concentration of about 31 mM) to the supernatant fluid to form an EDTA-fluid mixture;
 - f) mixing an aliquot of the EDTA-fluid mixture with a specific antibody and ¹²⁵I-probe solutions;
 - g) separating antibody-bound probe from unbound probe
20 and measuring the ¹²⁵I-probe in the antibody-bound probe fraction; and
 - h) comparing the measurement of step g to a standard.

1/22



Characteristics of immunogen and antibody:

1. Degree of substitution of immunogen = 20 moles peptide / mole thyroglobulin
2. Rabbit antiserum used at a final dilution of 1:18,000
3. Limit of Detection (80% binding) = 1.7 nM
4. Probe = (I¹²⁵) YRGSAGHATSESSV

FIG.1

2/22




FIG. 2







FIG. 4



4/22




FIG. 5




FIG. 6

SUBSTITUTE SHEET (RULE 26)




FIG. 7





FIG. 8

SUBSTITUTE SHEET (RULE 26)

6/22

FIG.9



SUBSTITUTE SHEET (RULE 26)

7/22




FIG.10





FIG.11

8/22

FIG. 12



SUBSTITUTE SHEET (RULE 26)

9/22




FIG. 13A




FIG. 13B




FIG. 13C

10/22

FIG. 14

42 kDa ►




FGN
FGN Digest

SUBSTITUTE SHEET (RULE 26)

11/22

FIG. 15



SUBSTITUTE SHEET (RULE 26)

12/22




FIG.16A

SUBSTITUTE SHEET (RULE 26)

13/22




FIG. 16B

14/22




FIG.17




FIG.18A

15/22




FIG. 18B

16/22




FIG.19A

SUBSTITUTE SHEET (RULE 26)

17/22





FIG.19B

18/22

FIG.20



19/22

Plasma A α (Val 360) nM Concentrations

Incubation Conditions	Found (nM)	Corrected (nM)	Expected (nM)	% Recovery
Blood (1 ml)	3.7	0	-	-
Blood + FD (9.7 pmoles)	20.9	17.2	15.9	108
Blood + sp (20 pmoles)	4.2	0.5	32.7	2
Blood (1 ml) + EDTA	3.9	0	-	-
Blood + EDTA + FD (9.7 pmoles)	19.7	15.8	15.9	99
Blood + EDTA + SP (20 pmoles)	26.6	22.7	32.7	69

FIG.21

20/22




FIG.22

SUBSTITUTE SHEET (RULE 26)

Date	Donor	PMN $\times 10^6$ /ml	A α (Vol ³⁶⁰)		A α (Vol ³⁶⁰)		Recovery %
			DMSO	A23187 pmoles/ml	DMSO	A23187 pmoles/ 1×10^6 PMN	
5-17-94	1(M)	4.7	5.1	66.1	1.1	14.1	101
7-29-94	1(M)	4.1	4.2	52.8	1.0	12.9	133
3-29-93	4(M)	2.6	6.3	36.8	2.4	14.1	74
4-25-94	4(M)	2.4	4.7	32.8	2.0	13.6	78
6-22-94	4(M)	2.9	4.6	38.3	1.6	13.2	108
3-22-94	5(M)	2.8	6.9	39.1	2.4	14.0	88
6-08-94	6(M)	2.6	3.5	40.7	1.3	15.6	121
5-12-94	8(M)	2.4	3.0	17.6	1.3	7.3	106
5-18-94	9(F)	3.5	4.0	16.8	1.2	4.8	102
6-22-94	10(M)	2.9	4.1	18.2	1.4	6.3	71
6-22-94	11(M)	2.8	4.5	24.1	1.6	8.6	91
7-21-94	12(M)	2.9	2.9	23.1	1.0	8.0	132
MEAN \pm SD		3.1 \pm 0.7	4.5 \pm 1.2	33.9 \pm 15.1	1.5 \pm 0.5	11.0 \pm 3.7	100 \pm 21

21/22

FIG.23

22/22

NUMBER OF SAMPLES		$A \alpha (Val^{360})$		
	TESTED	POSITIVE	MEAN	RANGE
Rheumatoid Arthritis	17	17	47	7-112
Gout	5	4	58	0-146
Osteoarthritis	4	0	0	-

FIG.24

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/13794

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : G01N 33/53, 33/555, 33/567; C07K 7/00

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/7.24, 7.9, 7.92, 13, 961; 436/69, 536; 530/329,330

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG

search terms: fibrinogen, elastase, PMNE, carboxy, A.alpha.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP, A, 0 345 906 (MERCK & CO., INC.) 13 December 1989, see entire document.	1-13
Y	JOURNAL OF LABORATORY AND CLINICAL MEDICINE, Volume 102, Number 6, issued November 1983, Plow et al., "Immunochemical discrimination of leukocyte elastase from plasmic degradation products of fibrinogen", pages 858-869, see pages 864-867.	1-13
X -- Y	BIOCHEMISTRY JOURNAL, Volume 281, issued 1992, Dewey et al., "Purification and characterization by fast-atom-bombardment mass spectrometry of the polymorphonuclear-leucocyte-elastase-generated Aa(1-21) fragment of fibrinogen from human blood after incubation with calcium ionophore A23187", pages 519-524, see pages 520-521.	1, 2, 4, 5, 7-9, 11 ----- 3, 10, 12, 13

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A		document defining the general state of the art which is not considered to be part of particular relevance
* E		earlier document published on or after the international filing date
* L		document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
* O		document referring to an oral disclosure, use, exhibition or other means
* P		document published prior to the international filing date but later than the priority date claimed
	* X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
	* Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
	* &	document member of the same patent family

Date of the actual completion of the international search

21 FEBRUARY 1996


Date of mailing of the international search report

12 MAR 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer


CAROL A. SPIEGEL

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/13794

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y	JOURNAL OF CLINICAL INVESTIGATION, Volume 78, issued July 1986, Weitz et al., "Development of an Assay for In Vivo Human Neutrophil Elastase Activity", pages 155-162, see pages 155, 158.	1, 2, 4, 5 ----- 3, 6-13
X, P ----- Y, P	BIOCHEMICAL PHARMACOLOGY, Volume 49, Number 10, issued 17 May 1995, Pacholok et al., "Formation of Polymorphonuclear Leukocyte Elastase: 1 Proteinase Inhibitor Complex and A (1-21) Fibrinopeptide in Human Blood Stimulated with the Calcium Ionophore A23187", pages 1513-1520, see entire document.	1, 2, 4, 5 ----- 3, 6-13
X	Biological Abstracts, Volume 84, Number 1, issued 01 July 1992, Nagamatsu et al., "Determination of leukocyte elastase concentration in plasma and serum by a simple method using a specific synthetic substrate", page 110, column 1, Abstract No. 1065, Haemostasis, 21 (6), pages 338-345, see entire abstract.	1
A	US, A, 5,157,019 (GLOVER et al.) 20 October 1992, see entire document.	1-13

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/13794

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

435/7.24, 7.9, 7.92, 13; 436/69, 536; 530/329,330